<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>00003 Mid Day Module (Pharma-3) - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / Mock Test / Mid Day Module
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">50</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "id": 3580,
    "choices": [
      {
        "id": 14299,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nesiritide</span></span></span></p>"
      },
      {
        "id": 14300,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sacubitril</span></span></span></p>"
      },
      {
        "id": 14301,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trimetazidine</span></span></span></p>"
      },
      {
        "id": 14302,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs are used for treatment of congestive heart failure except:</span></span></span></p>",
    "unique_key": "Q3873872",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407249,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Trimetazidine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Trimetazidine is an anti-anginal medication</strong> that <strong>improves myocardial glucose utilization </strong>by <strong>inhibiting fatty acid metabolism, </strong>leading to an <strong>energy-sparing effect in ischemic cells</strong>. However, it is <strong>not used </strong>in the treatment of <strong>congestive heart failure (CHF)</strong>; its <strong>primary use</strong> is in the management of <strong>angina pectoris.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Nesiritide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Nesiritide is a<strong> recombinant B-type natriuretic peptide</strong> that has <strong>vasodilatory effects </strong>and is used in the management of<strong> acute decompensated heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Sacubitril:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> When<strong> combined with valsartan</strong> (a <strong>neprilysin inhibitor and an angiotensin II receptor blocker, </strong>respectively), sacubitril is used to<strong> reduce the risk of cardiovascular death </strong>and<strong> hospitalization for heart failure in patients</strong> with <strong>chronic heart</strong> <strong>failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Metoprolol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Metoprolol is a<strong> beta-blocker </strong>that is used in the management of<strong> CHF.</strong> It <strong>reduces myocardial oxygen demand</strong> and can <strong>improve survival in patients with heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-094413.png\" style=\"height:849px; width:1000px\" /></span></u></strong></span></span></p>",
    "correct_choice_id": 14301,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3583,
    "choices": [
      {
        "id": 14311,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Losartan</span></span></span></p>"
      },
      {
        "id": 14312,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Telmisartan</span></span></span></p>"
      },
      {
        "id": 14313,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Candesartan</span></span></span></p>"
      },
      {
        "id": 14314,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Olmesartan</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Angiotensin receptor blocker which blocks thromboxane A2 receptor is?</span></span></span></p>",
    "unique_key": "Q3535972",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407250,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Losartan</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Losartan </strong>is the correct answer because it is<strong> not </strong>only an <strong>angiotensin receptor blocker (ARB)</strong> but also a <strong>competitive antagonist </strong>of the <strong>thromboxane A2 receptor</strong>. This <strong>dual action means</strong> that<strong> Losartan can block the effects of thromboxane A2</strong>, leading to an <strong>attenuation</strong> of <strong>platelet aggregation</strong>. Additionally, the<strong> metabolite of Losartan</strong> has the ability to <strong>reduce COX-2 mRNA upregulation</strong> and <strong>COX-dependent prostaglandin generation,</strong> which further contributes to its<strong> antiplatelet effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Telmisartan:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>because <strong>Telmisartan is known as a partial agonist of peroxisome proliferator-activated receptor</strong> <strong>gamma (PPAR-&gamma;),</strong> which differentiates it from Losartan and <strong>does not</strong> confer the ability to<strong> block the thromboxane A2 receptor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Candesartan:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>as <strong>Candesartan </strong>is an <strong>inactive ester </strong>prodrug that <strong>does not</strong> possess the ability to <strong>block the</strong> <strong>thromboxane A2 receptor.</strong> It is<strong> hydrolyzed</strong> to<strong> its active form </strong>within the body, which <strong>acts selectively </strong>on the<strong> angiotensin receptor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Olmesartan:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong> for this question since <strong>Olmesartan, </strong>while also being an<strong> inactive ester prodrug hydrolyzed </strong>to its <strong>active form</strong>, <strong>does not block the thromboxane A2 receptor.</strong> It is <strong>cleared by renal elimination</strong> and<strong> biliary excretion</strong> and <strong>does not</strong> require dose adjustment in patients with <strong>mild-to-moderate renal or hepatic impairment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Losartan</strong> is unique among <strong>angiotensin receptor blockers </strong>in that it also <strong>competitively antagonizes</strong> the <strong>thromboxane A2 receptor,</strong> contributing to its <strong>antiplatelet effects.</strong></span></span></span></p>",
    "correct_choice_id": 14311,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3586,
    "choices": [
      {
        "id": 14323,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clarithromycin</span></span></span></p>"
      },
      {
        "id": 14324,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oxycodone</span></span></span></p>"
      },
      {
        "id": 14325,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rivaroxaban </span></span></span></p>"
      },
      {
        "id": 14326,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adalimumab</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient is taking atorvastatin for dyslipidemia. Which of these drugs should be avoided in this patient?<strong> </strong></span></span></span></p>",
    "unique_key": "Q8659814",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407251,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Clarithromycin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Clarithromycin </strong>should be <strong>avoided</strong> in patients taking <strong>atorvastatin for dyslipidemia</strong>. Atorvastatin, like other <strong>statins,</strong> is <strong>metabolized</strong> by the <strong>cytochrome P450 3A4 (CYP3A4) enzyme system</strong>. Clarithromycin is a known <strong>inhibitor of the CYP3A4 enzyme,</strong> which can lead to <strong>increased plasma levels of atorvastatin.</strong> When its <strong>plasma levels rise </strong>significantly, there is an<strong> increased risk of serious adverse effects</strong> such as <strong>myopathy</strong>, which includes<strong> muscle pain, tenderness, or weakness</strong> with elevated levels of<strong> creatine kinase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Oxycodone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> because oxycodone, an<strong> opioid analgesic,</strong> <strong>does not</strong> significantly interact with the<strong> CYP3A4 enzyme</strong> in a way that would affect the <strong>metabolism of atorvastatin to a clinically relevant extent.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Rivaroxaban:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>as <strong>rivaroxaban,</strong> an <strong>anticoagulant</strong>, is<strong> not metabolized by CYP3A4</strong> in a way that would interfere with <strong>atorvastatin metabolism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Adalimumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> because <strong>adalimumab</strong>, an <strong>immunosuppressive drug</strong> used to treat <strong>autoimmune diseases, does not</strong> interact with the<strong> CYP3A4 enzyme </strong>and thus<strong> would not </strong>affect <strong>atorvastatin levels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When prescribing <strong>statins,</strong> <strong>avoid </strong>concomitant use with drugs that<strong> inhibit CYP3A4,</strong> such as <strong>clarithromycin,</strong> to prevent an<strong> increase</strong> in their <strong>plasma levels</strong> which could <strong>lead to myopathy. </strong>Other notable<strong> CYP3A4 inhibitors</strong> to avoid include <strong>amiodarone, gemfibrozil, HIV</strong> <strong>protease inhibitors (such as saquinavir, ritonavir), and itraconazole.</strong></span></span></span></p>",
    "correct_choice_id": 14323,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3588,
    "choices": [
      {
        "id": 14331,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a drug that can act by inhibiting angiotensin converting enzyme</span></span></span></p>"
      },
      {
        "id": 14332,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a drug used in combination with valsartan for congestive heart failure</span></span></span></p>"
      },
      {
        "id": 14333,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypokalemia is an adverse effect of sacubitril</span></span></span></p>"
      },
      {
        "id": 14334,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sacubitril is combined with ramipril for treatment of hypertension</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statement is True regarding Sacubitril?</span></span></span></p>",
    "unique_key": "Q1881193",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407252,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) It is a drug used in combination with valsartan for congestive heart failure</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sacubitril</strong> is a <strong>neprilysin inhibitor</strong> that <strong>increases </strong>the levels of <strong>natriuretic peptides </strong>by <strong>inhibiting their degradation</strong>. <strong>Neprilysin</strong> is responsible for <strong>degrading </strong>various peptides including <strong>natriuretic peptides, angiotensin II, bradykinin, and substance P.</strong> To counteract the potential excess of <strong>angiotensin II </strong>due to<strong> neprilysin inhibition, sacubitril </strong>is combined with an<strong> angiotensin receptor blocker (ARB),</strong> specifically <strong>valsartan.</strong> This combination, referred to as an <strong>angiotensin receptor-neprilysin inhibitor (ARNI),</strong> is approved for the treatment of<strong> heart failure. ARNI</strong> is specifically indicated to<strong> reduce the risk of cardiovascular death </strong>and <strong>hospitalization for heart</strong> failure in patients with<strong> chronic heart failure (NYHA Class II-IV) </strong>and<strong> reduced ejection fraction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect</strong> because <strong>sacubitril&nbsp;is not an angiotensin converting enzyme (ACE) inhibitor</strong>, which typically have names ending in -pril.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect </strong>as <strong>hypokalemia</strong>&nbsp;is <strong>not a side effect</strong> associated with <strong>sacubitril.</strong> It is <strong>more</strong> commonly associated with <strong>traditional</strong> <strong>diuretics </strong>rather than<strong> neprilysin inhibitors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>because <strong>sacubitril is combined with valsartan, not ramipril</strong>, and the combination is used for <strong>heart failure,</strong> not specifically for hypertension.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sacubitril is a neprilysin inhibitor </strong>used in combination<strong> with valsartan</strong> as an<strong> ARNI for the treatment of heart failure</strong> to <strong>reduce the risk</strong> of <strong>cardiovascular death and heart failure hospitalization</strong>, particularly in patients with<strong> reduced ejection fraction.</strong></span></span></span></p>",
    "correct_choice_id": 14332,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3598,
    "choices": [
      {
        "id": 14371,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></p>"
      },
      {
        "id": 14372,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone</span></span></span></p>"
      },
      {
        "id": 14373,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lignocaine</span></span></span></p>"
      },
      {
        "id": 14374,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phenytoin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the drug of choice for digoxin induced ventricular tachyarrhythmias?</span></span></span></p>",
    "unique_key": "Q4310077",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407253,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Lignocaine&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Lignocaine</strong> is the <strong>drug of choice</strong> for treating <strong>ventricular tachyarrhythmias</strong> induced by <strong>digoxin toxicity.</strong> It works by stabilizing the <strong>cardiac membrane</strong> and is effective in <strong>treating digoxin-induced arrhythmias</strong> <strong>without </strong>further<strong> inhibiting the AV conduction, </strong>which is often already <strong>compromised in digoxin toxicity.</strong> Its use in this context is based on its ability to selectively target the<strong> arrhythmogenic</strong> <strong>effects without exacerbating the digoxin effect</strong> on the <strong>AV node.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Quinidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Quinidine is an <strong>antiarrhythmic</strong> that can<strong> increase serum digoxin levels </strong>and is<strong> contraindicated in digoxin-induced arrhythmias</strong> because it may <strong>exacerbate toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Amiodarone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While amiodarone is a<strong> versatile antiarrhythmic agent </strong>used in <strong>various types of arrhythmias</strong>, it can <strong>interact</strong> with <strong>digoxin and increase its levels</strong>, potentially <strong>worsening toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Phenytoin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Phenytoin is effective for <strong>ventricular arrhythmias, </strong>especially in the context of<strong> acute myocardial infarction,</strong> but it is<strong> not the first choice for digoxin-induced arrhythmias.</strong> It <strong>can be used </strong>if<strong> lignocaine is not available or contraindicated.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>appropriate management of digoxin-induced ventricular tachyarrhythmias</strong>. Recognizing <strong>lignocaine </strong>as the<strong> drug of choice </strong>in this scenario is <strong>critical for effectively addressing the cardiac toxicity </strong>associated with <strong>digoxin</strong> <strong>overdose</strong>, <strong>minimizing the risk </strong>of further <strong>cardiac complications.</strong></span></span></span></p>",
    "correct_choice_id": 14373,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3617,
    "choices": [
      {
        "id": 14447,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin</span></span></span></p>"
      },
      {
        "id": 14448,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dobutamine</span></span></span></p>"
      },
      {
        "id": 14449,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amrinone</span></span></span></p>"
      },
      {
        "id": 14450,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drug is used in CHF for relief of congestive symptoms and restoration of cardiac performance but does not possess inotropic action?</span></span></span></p>",
    "unique_key": "Q6890522",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407254,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Metoprolol&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metoprolol, a beta-blocker,</strong> is used in the management of<strong> congestive heart failure (CHF)</strong> for the relief of <strong>congestive symptoms</strong> and <strong>restoration of cardiac performance</strong>, but it <strong>does no</strong>t have<strong> inotropic action</strong>. Instead, <strong>metoprolol</strong> works by <strong>blocking beta-adrenergic</strong> <strong>receptors in the heart,</strong> leading to a<strong> reduction in heart rate</strong>, <strong>decrease in cardiac workload, </strong>and <strong>improvement in cardiac efficiency</strong> over time. This mechanism helps in<strong> managing CHF without</strong> directly increasing the<strong> force of heart contractions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Digoxin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Digoxin has a <strong>positive inotropic effect</strong>, <strong>increasing the force of cardiac contractions</strong>, and is used in<strong> CHF to improve</strong> <strong>symptoms and cardiac performance.</strong> It<strong> does not </strong>fit the criteria as it possesses <strong>inotropic action.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Dobutamine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Dobutamine is a <strong>beta-1 adrenergic agonist </strong>with <strong>positive inotropic effects</strong>, used primarily in <strong>acute heart</strong> <strong>failure</strong> to <strong>increase cardiac output. </strong>It directly <strong>increases the force of heart contractions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Amrinone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amrinone is a <strong>phosphodiesterase inhibitor</strong> with <strong>positive inotropic and vasodilatory effects</strong>, used to <strong>improve</strong> <strong>cardiac output </strong>in heart failure patients. Like <strong>dobutamine and digoxin,</strong> it <strong>increases the force of cardiac contractions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the role of <strong>different classes of drugs</strong> in the management of <strong>CHF,</strong> particularly <strong>distinguishing</strong> those<strong> with and without inotropic action.</strong> <strong>Metoprolol&#39;s</strong> use in<strong> CHF illustrates</strong> the importance of managing <strong>heart rate and reducing</strong> <strong>myocardial oxygen demand</strong> as part of a strategy to <strong>improve cardiac performance</strong> <strong>without directly increasing the force of contraction</strong></span></span></span></p>",
    "correct_choice_id": 14450,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3629,
    "choices": [
      {
        "id": 14495,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary fibrosis</span></span></span></p>"
      },
      {
        "id": 14496,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corneal microdeposits</span></span></span></p>"
      },
      {
        "id": 14497,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Photosensitivity</span></span></span></p>"
      },
      {
        "id": 14498,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tachycardia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following are adverse effects of amiodarone except:</span></span></span></p>",
    "unique_key": "Q9450596",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407255,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Tachycardia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiodarone</strong> is a <strong>class III anti-arrhythmic</strong> drug known for its <strong>broad spectrum of action</strong>. <strong>Tachycardia is not an adverse effect</strong> of amiodarone; rather, the drug can <strong>cause bradycardia </strong>and may<strong> lead to a fall in blood pressure </strong>and <strong>myocardial depression</strong> when administered <strong>intravenously.</strong> This medication is <strong>notorious for a number of serious advrsee effects</strong>, particularly with <strong>prolonged use.</strong> The most severe include<strong> pulmonary fibrosis and alveolitis.</strong> <strong>Photosensitivity and skin pigmentation</strong> may occur in approximately 10% of patients taking amiodarone.<strong> Corneal microdeposits</strong> can result in <strong>vision disturbance</strong>s such as <strong>seeing halos around light</strong>s, commonly described as <strong>headlight dazzle,</strong> but this <strong>side effect is reversible upon discontinuation of the drug. </strong>Amiodarone may also cause<strong> peripheral neuropathy,</strong> which often presents as <strong>muscle weakness in the pelvic and shoulder regions</strong>. Additionally, it can <strong>interfere with thyroid function</strong> by <strong>preventing the peripheral conversion of thyroxine (T4) to triiodothyronine (T3), </strong>leading to <strong>hypothyroidism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pulmonary fibrosis:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is a<strong> serious and well-recognized side effect of amiodarone,</strong> especially with <strong>long-term use.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Corneal microdeposits:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Common </strong>and typically <strong>reversible upon discontinuation of the drug.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Photosensitivity:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This<strong> adverse effect</strong> can occur in patients taking amiodarone<strong>, leading to increased risk of sunburn and skin</strong> <strong>pigmentation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiodarone</strong> is a <strong>class III anti-arrhythmic drug</strong> associated with <strong>several adverse effects </strong>including <strong>pulmonary fibrosis, corneal</strong> <strong>microdeposits, and photosensitivity,</strong> but not tachycardia; <strong>in fact, it more commonly causes bradycardia.</strong></span></span></span></p>",
    "correct_choice_id": 14498,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3645,
    "choices": [
      {
        "id": 14559,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lignocaine</span></span></span></p>"
      },
      {
        "id": 14560,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propanolol</span></span></span></p>"
      },
      {
        "id": 14561,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Encainide</span></span></span></p>"
      },
      {
        "id": 14562,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A new antiarrhythmic drug is found to be effective against both atrial and ventricular arrhythmias. Its effect on action potential is shown in the Figure. The effect of this new drug is most like:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/image-2-min.jpg\" style=\"height:168px; width:400px\" /></span></span></span></p>",
    "unique_key": "Q6413034",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407256,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Quinidine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>graph</strong> provided<strong> shows an action potential curve </strong>with a<strong> prolonged plateau </strong>phase after<strong> drug therapy,</strong> which is characteristic of a drug that <strong>blocks potassium channels</strong>, thereby<strong> prolonging the duration of the action potential. </strong>The graph also depicts the <strong>decrease</strong> <strong>in slope of phase 0 </strong>which is characteristic of<strong> sodium channel blockers.</strong> This effect (<strong>sodium and potassium channel blockade</strong>) is seen with<strong> Class IA antiarrhythmic drugs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Among the options provided, <strong>Quinidine</strong> is <strong>known to have this effect on the action potential.</strong> Quinidine is a <strong>Class IA antiarrhythmic</strong> drug that <strong>not only blocks sodium channels (like Class I drugs) </strong>but also has the <strong>additional effect</strong> of <strong>blocking potassium channels,</strong> similar to<strong> Class III antiarrhythmics,</strong> which can lead to <strong>a prolonged action potential.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Lignocaine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Lignocaine (Lidocaine) is a <strong>Class IB antiarrhythmic drug</strong> that primarily works by <strong>shortening the action potential</strong> duration by <strong>blocking sodium channels</strong>, particularly in <strong>ischemic or depolarized cells</strong>. It<strong> does not</strong> prolong the <strong>action</strong> <strong>potential plateau.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Propranolol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Propranolol is a<strong> Class II antiarrhythmic</strong>, which is a <strong>beta-blocker </strong>that reduces<strong> sympathetic nervous system</strong> <strong>activity.</strong> It <strong>does not </strong>have a direct effect on the<strong> action potential duration or plateau phase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Encainide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Encainide</strong>, which is<strong> no longer widely used,</strong> was a<strong> Class IC antiarrhythmic drug </strong>that significantly slows conduction by<strong> blocking sodium channels</strong> but <strong>does not </strong>typically prolong the<strong> action potential duration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to recognize the<strong> electrophysiologic effects of antiarrhythmic drugs</strong> on the cardiac action potential. Understanding how these drugs affect the <strong>action potential</strong> can provide insights into their <strong>therapeutic uses and potential</strong> <strong>arrhythmogenic risks. Quinidine&#39;s</strong> effect of <strong>prolonging the action potential duration</strong> is useful in the treatment of <strong>both atrial and</strong> <strong>ventricular arrhythmias,</strong> but it also carries the<strong> risk of proarrhythmia, </strong>underlining the need for<strong> careful patient selection </strong>and <strong>monitoring.</strong></span></span></span></p>",
    "correct_choice_id": 14562,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3619,
    "choices": [
      {
        "id": 14455,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Bradycardiac agent</span></span></span></p>"
      },
      {
        "id": 14456,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Rho kinase inhibition</span></span></span></p>"
      },
      {
        "id": 14457,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">K channel opener</span></span></span></p>"
      },
      {
        "id": 14458,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Inhibiting mitochondrial LC3- KAT</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trimetazidine is a drug approved for the treatment of angina pectoris. Its mechanism of action is assumed to be:</span></span></span></p>",
    "unique_key": "Q9218784",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407257,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Inhibiting mitochondrial LC3-KAT&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Trimetazidine</strong> works through <strong>non-hemodynamic mechanisms,</strong> meaning it <strong>does not</strong> affect the determinants of <strong>myocardial oxygen</strong> consumption such as <strong>heart rate (HR) and blood pressure (BP) at rest or during exercise. </strong>Despite this, it<strong> reduces the frequency of</strong> <strong>angina attacks </strong>and <strong>increases exercise capacity. Trimetazidine&#39;s </strong>mechanism of action is <strong>postulated to enhance cellular tolerance </strong>to <strong>ischemia </strong>by<strong> inhibiting mitochondrial long-chain 3-ketoacyl-CoA thiolase (LC3-KAT),</strong> a key enzyme in <strong>fatty acid oxidation.</strong> This <strong>inhibition </strong>results in a shift from <strong>fatty acid metabolism to increased glucose metabolism in the myocardium. </strong>Since fatty acid <strong>oxidation requires more oxygen to produce the same amount of ATP as glucose</strong>, the <strong>shift to glucose metabolism</strong> leads to <strong>reduced</strong> <strong>oxygen demand</strong>. <strong>Trimetazidine</strong> is often referred to as a <strong>partial fatty acid oxidation (pFOX) inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect</strong> because<strong> ivabradine&nbsp;is the bradycardiac agent </strong>used <strong>for angina</strong>, which <strong>acts by blocking the funny current in the SA</strong> <strong>node</strong>, not trimetazidine.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect</strong> as<strong> fasudil&nbsp;</strong>is the<strong> rho kinase inhibitor utilized for angina pectoris</strong>, not trimetazidine.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect </strong>because <strong>nicorandil&nbsp;is the K channel opener </strong>(which also has<strong> nitric oxide releasing properties</strong>) that is<strong> used for</strong> <strong>angina pectoris, </strong>rather than trimetazidine.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Trimetazidine</strong> is an <strong>antianginal medication</strong> that <strong>reduces the frequency of angina attacks</strong> and <strong>increases exercise capacity </strong>through a mechanism that likely involves the <strong>inhibition of mitochondrial LC3-KAT, </strong>leading to a shift from <strong>fatty acid to glucose metabolism</strong> in the<strong> myocardium and resulting</strong> in a<strong> reduced oxygen demand.</strong></span></span></span></p>",
    "correct_choice_id": 14458,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3660,
    "choices": [
      {
        "id": 14619,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a BNP analogue</span></span></span></p>"
      },
      {
        "id": 14620,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be used in decompensated CHF</span></span></span></p>"
      },
      {
        "id": 14621,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be administered orally</span></span></span></p>"
      },
      {
        "id": 14622,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It causes loss of Na<sup>+</sup> in the urine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements about nesiritide are true except? </span></span></span></p>",
    "unique_key": "Q3052889",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407258,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) It can be administered orally</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nesiritide</strong> is<strong> not </strong>available in an <strong>oral formulation </strong>because it is a <strong>peptide </strong>(<strong>Note</strong>: Drugs ending with <strong>&lsquo;tide&rsquo; are peptides)</strong>. <strong>Nesiritide</strong> is administered<strong> intravenously.</strong> It is a <strong>recombinant</strong> form of <strong>B-type natriuretic peptide (BNP),</strong> which is naturally produced by the <strong>ventricles of the heart.</strong> The <strong>intravenous administration </strong>is necessary because <strong>peptides typically undergo rapid degradation</strong> in the <strong>gastrointestinal tract</strong> and would be ineffective if administered orally.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. It is a BNP analogue:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true. Nesiritide</strong> is a <strong>synthetic</strong> version of <strong>BNP</strong> that is used in the management of <strong>acute decompensated heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. It can be used in decompensated CHF:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. <strong>Nesiritide</strong> is indicated for the <strong>treatment of acute</strong> <strong>decompensated congestive heart failure (CHF),</strong> where it works by causing<strong> vasodilation and natriuresis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. It causes loss of Na+ in the urine:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. Nesiritide promotes <strong>natriuresis,</strong> which is the<strong> excretion of sodium</strong> in the <strong>urine</strong>, contributing to its <strong>beneficial effects in heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>administration and effects of nesiritide </strong>in the treatment of<strong> acute decompensated heart</strong> <strong>failure</strong>. Nesiritide must be <strong>administered intravenously </strong>due to its <strong>peptide</strong> nature and the <strong>gastrointestinal degradation of oral peptides</strong></span></span></span></p>",
    "correct_choice_id": 14621,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3722,
    "choices": [
      {
        "id": 14867,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Guanylyl cyclase</span></span></span></p>"
      },
      {
        "id": 14868,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phosphokinase 1,2</span></span></span></p>"
      },
      {
        "id": 14869,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phospholipase A</span></span></span></p>"
      },
      {
        "id": 14870,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phospholipase B</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sodium nitroprusside acts by stimulation of?</span></span></span></p>",
    "unique_key": "Q5804759",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407259,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Guanylyl cyclase</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sodium nitroprusside</strong> acts by directly <strong>stimulating guanylyl cyclase </strong>in<strong> vascular smooth muscle cells</strong>. This stimulation leads to an <strong>increase in intracellular cyclic guanosine monophosphate (cGMP),</strong> which then <strong>activates protein kinase G (PKG).</strong> The <strong>activation </strong>of <strong>PKG</strong> results in the <strong>dephosphorylation of myosin light chains</strong> in the smooth muscle, which <strong>induces relaxation and vasodilation. </strong>Due to this mechanism, <strong>sodium nitroprusside </strong>is effective in <strong>rapidly reducing blood pressure </strong>in <strong>hypertensive emergencies.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Phosphokinase 1,2:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> There is<strong> no </strong>enzyme specifically named <strong>phosphokinase 1,2. </strong>This option <strong>does not</strong> relate to the known mechanism of action of sodium nitroprusside.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Phospholipase A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Phospholipase A is an enzyme </strong>that <strong>hydrolyzes phospholipids</strong> to produce <strong>fatty acids</strong> and <strong>lysophospholipids</strong>. It is<strong> not </strong>directly involved in the <strong>mechanism of action of sodium nitroprusside.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Phospholipase B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Phospholipase B also <strong>acts on phospholipids </strong>but is<strong> not</strong> related to the<strong> vasodilatory action of sodium</strong> <strong>nitroprusside.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>pharmacodynamics of sodium nitroprusside</strong>, a <strong>potent vasodilator. </strong>By knowing that its mechanism involves th<strong>e stimulation of guanylyl cyclase </strong>and the subsequent<strong> increase in cGMP, </strong>healthcare professionals can better anticipate its effects and necessary precautions, such as <strong>monitoring for signs of cyanide toxicity</strong> due to its metabolism. Understanding the<strong> differences in mechanisms</strong> among various<strong> vasodilators </strong>is crucial for <strong>selecting the appropriate agent </strong>in clinical scenarios.</span></span></span></p>",
    "correct_choice_id": 14867,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3735,
    "choices": [
      {
        "id": 14919,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin</span></span></span></p>"
      },
      {
        "id": 14920,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Furosemide</span></span></span></p>"
      },
      {
        "id": 14921,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol succinate</span></span></span></p>"
      },
      {
        "id": 14922,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dobutamine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following medications has been shown to reduce mortality in heart failure with reduced ejection fraction?</span></span></span></p>",
    "unique_key": "Q9131620",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407260,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Metoprolol succinate</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metoprolol succinate</strong>, a <strong>beta-1 selective adrenergic receptor blocker,</strong> has been shown in clinical trials to<strong> reduce mortality in patients</strong> with heart failure with reduced ejection fraction (HFrEF). It works by reducing the effects of <strong>catecholamines (stress</strong> <strong>hormones) on the heart, </strong>which in the setting of <strong>heart failure can be detrimental over time</strong>. By<strong> decreasing heart rate and myocardial</strong> <strong>contractility, </strong>it <strong>reduces myocardial oxygen demand </strong>and can<strong> improve the function of the heart.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Digoxin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While digoxin can<strong> improve symptoms and reduce hospitalizations by increasing the force of cardiac c</strong>ontractions and <strong>controlling heart rate</strong> in patients with <strong>heart failure,</strong> it<strong> has not been shown to reduce mortality </strong>in these patients.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Furosemide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Furosemide is a<strong> loop diuretic</strong> that is used to<strong> reduce symptoms of congestion in heart failure </strong>by promoting the<strong> excretion of sodium and water</strong>. However, it <strong>does not</strong> have a<strong> direct effect on reducing mortality in heart failure</strong> with <strong>reduced</strong> <strong>ejection fraction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Dobutamine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Dobutamine is a<strong> beta-1 agonist</strong> used in <strong>acute heart failure to increase cardiac output</strong>. It is generally used for <strong>short-term support in hospitalized patients</strong> and is <strong>not </strong>shown to<strong> reduce long-term mortality in chronic heart failure</strong>; its long-term use can actually be<strong> harmful due to increased cardiac oxygen demand </strong>and potential for<strong> arrhythmia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the role of <strong>different classes of drugs </strong>in the treatment of <strong>heart failure</strong> with <strong>reduced ejection</strong> <strong>fraction,</strong> particularly those that <strong>have been demonstrated to reduce mortality.</strong> </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs reducing mortality in CHF include:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta blockers</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACE inhibitors</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ARBs</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aldosterone antagonists</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ivabradine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydralazine + Isosorbide dinitrate</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 14921,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3745,
    "choices": [
      {
        "id": 14959,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Coronary vasodilation</span></span></span></p>"
      },
      {
        "id": 14960,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decrease heart rate</span></span></span></p>"
      },
      {
        "id": 14961,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased afterload</span></span></span></p>"
      },
      {
        "id": 14962,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreases preload</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The primary mechanism of action of nitrates in a patient of classical angina is:&nbsp;</span></span></span></p>",
    "unique_key": "Q4287837",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407261,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Decreases preload</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>primary action of nitrates</strong> in the treatment of <strong>classical angina</strong> is <strong>to decrease preload</strong>. <strong>Nitrates</strong> cause<strong> venous dilation,</strong> which reduces the <strong>volume of blood returning to the heart.</strong> This action <strong>decreases the heart&#39;s workload</strong> and its <strong>demand for oxygen,</strong> thereby <strong>alleviating the symptoms of angina</strong>. Please note, if nothing is mentioned in question, angina should be considered as classical angina.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Coronary Vasodilation</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Nitrates do </strong>cause some <strong>coronary vasodilation,</strong> but this is <strong>not their primary action</strong> in treating <strong>classical angina.</strong> <strong>Endothelium independent coronary vasodilation</strong> is the <strong>primary </strong>mechanism of <strong>nitrates </strong>in treatment of <strong>variant</strong> <strong>angina.</strong>&nbsp;In a typical vascular system, the<strong> endothelium</strong> plays a crucial role in <strong>regulating blood vessel tone and blood flow</strong>. It does this by releasing substances like<strong> nitric oxide (NO), </strong>which<strong> promote vasodilation.</strong>&nbsp;However, <strong>nitrates work independently of the endothelial</strong> <strong>cells.</strong> They are<strong> converted into nitric oxide (NO)</strong> <strong>within</strong> the <strong>smooth muscle cells.</strong> This<strong> NO</strong> then activates an enzyme called <strong>guanylate cyclase</strong>, which <strong>increases the levels of cyclic guanosine monophosphate (cGMP).</strong> The <strong>increase in cGMP </strong>leads to relaxation of the<strong> smooth muscle cells</strong>, resulting in <strong>vasodilatio</strong>n. This mechanism is particularly important in conditions like <strong>variant angina,</strong> where there are<strong> episodes of coronary artery spasm</strong>. <strong>Nitrate</strong>s can effectively <strong>relax the smooth muscle </strong>in the<strong> coronary arteries,</strong> <strong>reducing the spasm</strong> and thus <strong>alleviating the angina pain</strong>. This action is <strong>independent </strong>of the <strong>endothelium,</strong> which may <strong>not </strong>be <strong>functioning optimally </strong>in all individuals with <strong>coronary artery disease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Decrease Heart Rate</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Nitrates <strong>do not</strong> have a significant effect on<strong> heart rate. </strong>Drugs that <strong>primarily decrease heart rate</strong>, such as <strong>beta-blockers</strong>, are used separately for this purpose in the management of angina.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Decrease Afterload</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While<strong> nitrates</strong> can have a <strong>minor effect on afterload </strong>due to <strong>systemic vasodilation</strong>, <strong>decreasing</strong> <strong>afterload</strong> is <strong>not </strong>their primary mechanism of action in<strong> treating angina</strong>. Medications like <strong>ACE inhibitors or angiotensin receptor</strong> <strong>blockers</strong> are<strong> more </strong>effective for this purpose.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>mechanism of action of nitrates</strong> in <strong>classical angina is decrease in preload.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>mechanism of action of nitrates</strong> i<strong>n variant angina</strong> is<strong> endothelium independent coronary vasodilation.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 14962,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3749,
    "choices": [
      {
        "id": 14975,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduce the dose of ACE inhibitor</span></span></span></p>"
      },
      {
        "id": 14976,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Add anti- tussive for treatment of cough</span></span></span></p>"
      },
      {
        "id": 14977,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Change to Angiotensin receptor blocker (ARB)</span></span></span></p>"
      },
      {
        "id": 14978,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Order for a CT scan of chest</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old patient with essential hypertension on ACE inhibitors for 6 months developed chronic refractory dry cough. What would be the correct action to be taken?</span></span></span></p>",
    "unique_key": "Q4179287",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407262,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Change to Angiotensin receptor blocker (ARB)</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Angiotensin-converting enzyme (ACE) inhibitors </strong>are known to induce a <strong>dry cough </strong>in approximately<strong> 5&ndash;10% of patients</strong>. The mechanism behind this adverse effect is thought to be related to the <strong>accumulation of bradykinin</strong>, which is <strong>not broken down</strong> as efficiently due to the<strong> inhibition of ACE.</strong> This <strong>side effect </strong>occurs more frequently in <strong>women</strong> than men and is <strong>not dose-related</strong>, as it can develop anytime between<strong> 1 week and 6 months after starting the therapy. </strong>In some cases, the<strong> persistent cough requires the cessation</strong> of<strong> ACE inhibitor therapy. </strong>It has been noted that <strong>once ACE inhibitors</strong> are stopped, the cough usually resolves within 4 days. Alternative medications like<strong> ARBs do not inhibit </strong>the <strong>degradation of bradykinin </strong>and are thus <strong>not </strong>associated with the <strong>side effect </strong>of a <strong>dry cough,</strong> making them a <strong>suitable alternative for hypertension management in patients </strong>who develop a <strong>cough with ACE inhibitors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Reduce the dose of ACE inhibitor:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Reducing the dose of the ACE inhibitor <strong>would not alleviate the cough </strong>since the adverse effect is not dose-related and the patient has already developed sensitivity to the drug.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Add anti-tussive for the treatment of cough:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> An anti-tussive <strong>would not</strong> address the underlying <strong>cause of the cough, </strong>which in this case is <strong>due to the ACE inhibitors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Order for a CT scan of the chest:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A CT scan would be an <strong>unnecessary investigation </strong>and an additional cost burden for the patient, given that the cause of the <strong>chronic cough is already known to be drug-related </strong>and<strong> not indicative of an underlying</strong> <strong>pulmonary pathology.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a patient who develops a <strong>chronic dry cough while on ACE inhibitors, </strong>changing to an <strong>Angiotensin receptor blocker (ARB)</strong> is the <strong>correct course of action,</strong> a<strong>s ARBs do not </strong>cause this<strong> side effect.</strong></span></span></span></p>",
    "correct_choice_id": 14977,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3755,
    "choices": [
      {
        "id": 14999,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></p>"
      },
      {
        "id": 15000,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lignocaine</span></span></span></p>"
      },
      {
        "id": 15001,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ciprofloxacin</span></span></span></p>"
      },
      {
        "id": 15002,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs can result in prolongation of QT interval in ECG?</span></span></span></p>",
    "unique_key": "Q1108176",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407263,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Quinidine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Quinidine</strong> is a<strong> class Ia anti-arrhythmic drug</strong> that acts by<strong> blocking Na+ (sodium) and K+ (potassium) channels</strong>. The blocking of <strong>potassium channels </strong>is particularly important in the context of the question as it can affect the<strong> repolarization phase of the cardiac</strong> <strong>action potential, </strong>which is reflected as<strong> QT interval on an electrocardiogram (ECG). Prolonged repolarization</strong> leads to a<strong> prolonged QT</strong> <strong>interval</strong>, which can predispose to a <strong>type of ventricular tachycardia</strong> called <strong>Torsades de Pointes</strong>, a potentially <strong>life-threatening</strong> <strong>condition.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Lignocaine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Lignocaine (also known as lidocaine) is a<strong> class Ib anti-arrhythmic drug</strong> that predominantly <strong>blocks Na+ channels</strong> and is<strong> less </strong>likely to cause <strong>QT prolongation </strong>as its action is<strong> more specific to the fast sodium channels</strong> and it actually tends to <strong>shorten the action potential duration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ciprofloxacin:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ciprofloxacin is a <strong>fluoroquinolone antibiotic</strong>. Although fluoroquinolones like <strong>sparfloxacin, levofloxacin, and</strong> <strong>moxifloxacin</strong> are associated with <strong>QT prolongation, ciprofloxacin is less</strong> implicated in causing this <strong>adverse effect</strong> when compared to other drugs in its class.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Propranolol:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Propranolol is a<strong> non-selective beta-blocker</strong> and is <strong>not</strong> commonly associated with<strong> QT prolongation</strong>. It acts on the <strong>beta-adrenergic receptors </strong>and can affect<strong> heart rate and contractility</strong> but <strong>not</strong> typically the <strong>QT interval.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Quinidine,</strong> a <strong>class Ia anti-arrhythmic drug</strong>, can cause<strong> QT interval prolongation on an ECG</strong> due to its<strong> blockade of potassium channels,</strong> which affects the<strong> repolarization phase of the cardiac action potential.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-113043.png\" style=\"height:486px; width:1000px\" /></span></span></span></p>",
    "correct_choice_id": 14999,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3768,
    "choices": [
      {
        "id": 15051,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chlorthalidone</span></span></span></p>"
      },
      {
        "id": 15052,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triamterene</span></span></span></p>"
      },
      {
        "id": 15053,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone</span></span></span></p>"
      },
      {
        "id": 15054,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Furosemide</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preferred drug for the treatment of uncomplicated grade 2 hypertension in a 48-year-old man is? </span></span></span></p>",
    "unique_key": "Q1827121",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407264,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Chlorthalidone</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Chlorthalidone</strong> is a <strong>thiazide-like diuretic</strong> that is often preferred for the initial treatment of <strong>hypertension</strong>, including <strong>grade 2</strong> <strong>hypertension, </strong>which is defined as a<strong> systolic blood pressure of 140-159 mmHg or a diastolic blood pressure of 90-99 mmHg</strong>. <strong>Chlorthalidone </strong>helps to <strong>lower blood pressure by promoting the excretion of sodium and water</strong>, which<strong> reduces the volume of fluid in the blood vessels and lowers blood pressure</strong>. Its <strong>long half-life </strong>and evidence for <strong>reducing cardiovascular outcomes </strong>make it a suitable option for managing <strong>uncomplicated hypertension.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Triamterene:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Triamterene is a<strong> potassium-sparing diuretic</strong> that is<strong> not</strong> typically used as <strong>first-line treatment for hypertension.</strong> It is often<strong> used in combination</strong> with other <strong>diuretics to prevent hypokalemia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Spironolactone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Spironolactone is another <strong>potassium-sparing diuretic </strong>that also<strong> blocks the effects of aldosterone</strong>. While it can be used for <strong>hypertension</strong>, it is usually reserved for cases that are <strong>resistant to other treatments </strong>or for <strong>specific conditions like</strong> <strong>primary hyperaldosteronism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Furosemide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Furosemide is a<strong> loop diuretic</strong> that is primarily used for the treatment of <strong>edema associated with heart failure</strong> or <strong>renal disease.</strong> It is<strong> not</strong> typically used as<strong> first-line treatment for uncomplicated hypertension</strong> due to its<strong> shorter duration of action and </strong>greater risk for<strong> electrolyte imbalances.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to identify the preferred <strong>initial treatment</strong> options for <strong>hypertension. </strong>Thiazide-like diuretics such as <strong>chlorthalidone are recommended as first-line therapy</strong> for most patients with<strong> hypertension</strong> due to their effectiveness in<strong> lowering</strong> <strong>blood pressure and reducing the risk of cardiovascular events. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FIRST LINE DRUGS FOR DIFFERENT PATIENTS WITH HYPERTENSION</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-114419.png\" style=\"height:330px; width:1000px\" /></span></strong></span></span></p>",
    "correct_choice_id": 15051,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3772,
    "choices": [
      {
        "id": 15067,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone</span></span></span></p>"
      },
      {
        "id": 15068,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiloride</span></span></span></p>"
      },
      {
        "id": 15069,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nicorandil</span></span></span></p>"
      },
      {
        "id": 15070,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methyldopa</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs act as K channel opener? </span></span></span></p>",
    "unique_key": "Q9655821",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407265,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Nicorandil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nicorandil </strong>is recognized for its distinctive role as a <strong>potassium (K) channel opener. </strong>By activating these channels, nicorandil causes the <strong>hyperpolarization of vascular smooth muscle cells,</strong> which leads to the<strong> relaxation and vasodilation of both arterial and venous blood vessels</strong>. This vasodilatory effect contributes to a<strong> reduction in the myocardial oxygen demand and</strong> <strong>enhances the blood flow to</strong> <strong>areas</strong> of the<strong> heart muscle that are ischemic. </strong>The<strong> efficacy of nicorandil </strong>in the treatment of<strong> angina pectoris is not solely </strong>due to its <strong>potassium channel opening </strong>properties; it also possesses <strong>nitrate-like properties</strong> that further amplify its <strong>anti-anginal effects </strong>by <strong>reducing preload and afterload on the heart.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Spironolactone:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Spironolactone is a<strong> potassium-sparing diuretic</strong> that works <strong>at the level of the distal convoluted tubule</strong> in the kidneys but <strong>does not act </strong>as a<strong> K channel opener</strong> in the cardiovascular system.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Amiloride:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amiloride is also a <strong>potassium-sparing diuretic</strong> that affects <strong>ion channels in the kidneys</strong>, but again, it <strong>does not</strong> <strong>open potassium channels </strong>in vascular smooth muscle.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Methyldopa:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Methyldopa is an <strong>antihypertensive medication</strong> that <strong>acts centrally as an alpha-2 agonist</strong> to<strong> lower blood</strong> <strong>pressure</strong>. It<strong> does not</strong> have<strong> K channel opening properties.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nicorandil</strong> acts as a<strong> K channel opener and has nitrate-like properties, </strong>making it effective in the <strong>treatment of angina pectoris</strong> due to its ability to <strong>reduce myocardial oxygen demand </strong>and<strong> increase blood flow to the ischemic heart muscle.</strong></span></span></span></p>",
    "correct_choice_id": 15069,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3780,
    "choices": [
      {
        "id": 15099,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone</span></span></span></p>"
      },
      {
        "id": 15100,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenosine</span></span></span></p>"
      },
      {
        "id": 15101,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tenecteplase</span></span></span></p>"
      },
      {
        "id": 15102,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Verapamil</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55 yr. old male presented to emergency with severe acute chest pain, radiating to left shoulder and back in the last 20 minutes. It was associated with sweating. ECG is shown in the figure. Which of the following drug should be given to the patient?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/42.jpg\" style=\"height:243px; width:500px\" /></span></span></span></p>",
    "unique_key": "Q4556105",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407266,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Tenecteplase</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The description of the<strong> patient&#39;s symptoms</strong> along <strong>with the ECG (ST segment elevation in lead V1 to V5) </strong>makes the diagnosis of <strong>ST-segment elevation myocardial infarction (STEMI)</strong>. It would indicate the need for<strong> immediate reperfusion therapy. Tenecteplase </strong>is a <strong>fibrin-specific thrombolytic agent</strong> used in the management of <strong>STEMI </strong>to achieve <strong>reperfusion of the occluded coronary artery</strong>. It is given when <strong>primary percutaneous coronary intervention (PCI) </strong>is <strong>not </strong>available within the <strong>ideal time frame.</strong> <strong>Tenecteplase</strong> is <strong>administered </strong>to dissolve the<strong> thrombus</strong> that is<strong> blocking the coronary artery </strong>and causing the<strong> myocardial infarction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Amiodarone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amiodarone is an <strong>antiarrhythmic medication</strong> that is<strong> not </strong>indicated as an initial treatment for <strong>acute</strong> <strong>myocardial infarction</strong> unless there are accompanying<strong> life-threatening arrhythmias.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Adenosine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Adenosine is typically<strong> used </strong>in the treatment of certain forms of <strong>supraventricular tachycardia </strong>and <strong>not</strong> in the setting<strong> </strong>of<strong> acute myocardial infarction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Verapamil:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Verapamil is a <strong>calcium channel blocker </strong>that is generally<strong> contraindicated</strong> in the setting of <strong>acute myocardial</strong> <strong>infarction,</strong> especially with evidence of<strong> STEMI,</strong> as it can further <strong>depress myocardial contractility</strong> and <strong>lead to hemodynamic</strong> <strong>deterioration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The objective is to recognize the <strong>appropriate use of thrombolytic therapy</strong> in the treatment of<strong> STEMI when PCI is not immediately</strong> <strong>available.</strong> <strong>Prompt</strong> initiation of<strong> thrombolytic therapy</strong> can significantly<strong> improve outcomes in STEMI </strong>by restoring <strong>coronary blood flow</strong> and <strong>minimizing myocardial damage.</strong></span></span></span></p>",
    "correct_choice_id": 15101,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3795,
    "choices": [
      {
        "id": 15159,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nimodipine</span></span></span></p>"
      },
      {
        "id": 15160,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amlodipine</span></span></span></p>"
      },
      {
        "id": 15161,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diltiazem</span></span></span></p>"
      },
      {
        "id": 15162,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Verapamil</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is used for reversal of cerebral vasospasm and infarct following subarachnoid hemorrhage? </span></span></span></p>",
    "unique_key": "Q9791712",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407267,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Nimodipine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nimodipine </strong>is a <strong>cerebroselective calcium channel blocker </strong>with a particular affinity for <strong>cerebral blood vessels.</strong> Its use is indicated for the management of <strong>cerebral vasospasm</strong>, which is a complication that can follow <strong>subarachnoid hemorrhage. </strong>This vasospasm typically <strong>manifests 4-5 days after the hemorrhage</strong>, potentially leading to <strong>cerebral ischemia, infarction, and neurological deficits</strong>. <strong>Nimodipine&#39;s </strong>action of <strong>blocking calcium influx into vascular smooth muscle</strong> leads to the <strong>relaxation of these vessels,</strong> thereby <strong>mitigating vasospasm</strong> and<strong> reducing the risk of infarction </strong>and its associated <strong>morbidity and mortality</strong>. This action makes it a valuable agent in<strong> improving neurological </strong>outcomes following a <strong>subarachnoid hemorrhage.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Amlodipine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While amlodipine is also a <strong>calcium channel blocker</strong>, it is not specifically indicated for<strong> cerebral vasospasm.</strong> It is more commonly used for<strong> hypertension and coronary artery disease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Diltiazem:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Diltiazem is another <strong>calcium channel blocker</strong> with a <strong>broader cardiovascular effect profile </strong>and is <strong>not </strong>the drug of choice for<strong> cerebral vasospasm.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Verapamil:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Verapamil is a<strong> non-selective calcium channel blocker </strong>and is <strong>not</strong> specifically recommended for the treatment of <strong>cerebral vasospasm </strong>following <strong>subarachnoid hemorrhage.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nimodipine</strong> is used for the<strong> reversal of cerebral vasospasm and reducing mortality</strong> after <strong>subarachnoid hemorrhage,</strong> due to its s<strong>elective action on cerebral blood vessels.</strong></span></span></span></p>",
    "correct_choice_id": 15159,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3801,
    "choices": [
      {
        "id": 15183,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazides</span></span></span></p>"
      },
      {
        "id": 15184,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta adrenergic blocker</span></span></span></p>"
      },
      {
        "id": 15185,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACE inhibitor</span></span></span></p>"
      },
      {
        "id": 15186,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diazoxide</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with concomitant diabetes, anti-hypertensive agent of choice is? </span></span></span></p>",
    "unique_key": "Q9464287",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407268,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) ACE inhibitor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>ACE inhibitors</strong> are the preferred choice for<strong> hypertensive patients</strong> with <strong>diabetes </strong>because they have <strong>protective effects on the kidneys,</strong> which are often compromised in diabetic patients. They <strong>reduce blood pressure and decrease the progression of diabetic nephropathy</strong> by <strong>reducing intraglomerular pressure and proteinuria.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Thiazides:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Thiazide diuretics are effective <strong>antihypertensive</strong> agents but can<strong> affect carbohydrate metabolism </strong>and are <strong>not</strong> the<strong> first choice in patients with diabetes</strong>, as they can potentially <strong>worsen glycemic control.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Beta adrenergic blocker:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Beta-blockers <strong>can mask</strong> symptoms of <strong>hypoglycemia</strong> and may also affect <strong>lipid metabolism.</strong> Although they are<strong> effective for blood pressure control,</strong> they are<strong> not </strong>typically the<strong> first-line choice in diabetic patients</strong> unless there are<strong> other compelling indications such as heart failure or post-myocardial infarction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Diazoxide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Diazoxide is a<strong> vasodilator</strong> that can actually<strong> increase blood sugar levels </strong>by <strong>inhibiting insulin release </strong>from the <strong>pancreas</strong>. It is <strong>not </strong>used for routine treatment of <strong>hypertension </strong>and is certainly<strong> not the drug of choice in patients with diabetes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>appropriate choice of antihypertensive medication in patients with diabetes</strong>. <strong>ACE</strong> <strong>inhibitors offer renal protection </strong>and <strong>do not</strong> worsen <strong>glycemic control,</strong> making them a superior option for this patient population. Other properties of ACE inhibitors are also important for entrance exams.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Properties of ACE inhibitors</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>C</strong>ough</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>A</strong>ngioedema</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">P&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>P</strong>rodrugs (except captopril and Lisinopril)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>T</strong>aste disturbances</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">O&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>O</strong>rthostatic hypotension (when combined with diuretics)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">P&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>P</strong>regnancy (contra- indicated)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">R&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- bilateral&nbsp;<strong>R</strong>enal artery stenosis (contra-indicated)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">I&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>I</strong>ncreased K+ (contra-indicated)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">L&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>L</strong>ower the risk of diabetic nephropathy (Preferred drug in diabetic patients with hypertension)</span></span></span></p>",
    "correct_choice_id": 15185,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3808,
    "choices": [
      {
        "id": 15211,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fasudil</span></span></span></p>"
      },
      {
        "id": 15212,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranolazine</span></span></span></p>"
      },
      {
        "id": 15213,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trimetazidine</span></span></span></p>"
      },
      {
        "id": 15214,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ivabradine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a Rho kinase inhibitor?</span></span></span></p>",
    "unique_key": "Q4232288",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407269,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Fasudil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Fasudil </strong>is a <strong>Rho kinase inhibitor. </strong>Rho kinase is an<strong> enzyme</strong> that plays a significant role in<strong> smooth muscle contraction </strong>and other <strong>cellular processes</strong>. <strong>Inhibition</strong> of <strong>Rho kinase</strong> by <strong>fasudil </strong>leads to<strong> vasodilation</strong> making it useful for treatment of<strong> angina pectoris. </strong>It is also being investigated for the treatment of various <strong>cardiovascular disorders, including hypertension and pulmonary arterial</strong> <strong>hypertension, </strong>as well as for the<strong> prevention of cerebral vasospasm </strong>following<strong> subarachnoid hemorrhage.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Ranolazine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ranolazine is an<strong> anti-anginal medication. </strong>It works by<strong> inhibiting the late phase of the sodium </strong>current in the <strong>cardiac myocytes</strong>, thus <strong>reducing intracellular calcium overload </strong>and <strong>myocardial oxygen consumption.</strong> It <strong>does not</strong> act as a<strong> Rho kinase</strong> <strong>inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Trimetazidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Trimetazidine is an <strong>anti-ischemic (anti-anginal) metabolic agent</strong> that <strong>improves myocardial glucose</strong> utilization through<strong> inhibition of fatty acid metabolism.</strong> This action helps to<strong> maintain energy production in ischemic heart cells.</strong> <strong>Trimetazidine is not a Rho kinase inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ivabradine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ivabradine is a<strong> heart rate-reducing agent</strong> that works by<strong> inhibiting the If (funny) channel in the sinoatrial node</strong> <strong>of the heart</strong>, leading to a <strong>reduction in heart rate and myocardial oxygen demand.</strong> It is used for the treatment of <strong>chronic heart failure</strong> and <strong>stable angina pectoris</strong> in patients who<strong> cannot take beta-blockers</strong>. <strong>Ivabradine is not a Rho kinase inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the<strong> different mechanisms of action </strong>of various <strong>anti-anginal drugs. Fasudil as a Rho kinase</strong> <strong>inhibitor contrasts </strong>with<strong> ranolazine, trimetazidine, and ivabradine, </strong>which have different mechanisms. </span></span></span></p>",
    "correct_choice_id": 15211,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3817,
    "choices": [
      {
        "id": 15247,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flecainide</span></span></span></p>"
      },
      {
        "id": 15248,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tocainide</span></span></span></p>"
      },
      {
        "id": 15249,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Procainamide</span></span></span></p>"
      },
      {
        "id": 15250,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ibutilide</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the antiarrhythmic agent with the following mechanism of action? </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/14/whatsapp-image-2024-02-14-at-35057-pm.jpeg\" style=\"height:225px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q5340411",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407270,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Flecainide</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The graph shows an<strong> action potential of a cardiac myocyte</strong> with a marked <strong>block of sodium channels </strong>and <strong>no change in the</strong> <strong>repolarization phase</strong>. This description is consistent with the action of<strong> Class IC antiarrhythmic drugs,</strong> which significantly<strong> slow the</strong> <strong>conduction of the cardiac impuls</strong>e through the<strong> myocardium by blocking sodium channels without </strong>affecting the <strong>duration of the</strong> <strong>action potential. Flecainide</strong> is a<strong> Class IC antiarrhythmic drug</strong> that exhibits a marked<strong> blockade of sodium channels,</strong> which <strong>slows</strong> <strong>conduction throughout the heart</strong>. It <strong>does not</strong> significantly prolong the<strong> action potential </strong>or <strong>affect repolarization</strong>, which is consistent with the graph shown.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Tocainide:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tocainide is a <strong>Class IB antiarrhythmic agent.</strong> Class IB drugs tend to <strong>shorten the action potential </strong>duration rather than having <strong>no change in repolarization.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Procainamide:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Procainamide is <strong>a Class IA antiarrhythmic agent</strong> that <strong>not only blocks sodium channels</strong> but also has a <strong>moderate effect on repolarization,</strong> leading to a<strong> slight prolongation of the action potential,</strong> which is not depicted in the graph.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ibutilide:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ibutilide is a<strong> Class III antiarrhythmic drug</strong> that acts by <strong>prolonging repolarization</strong> through<strong> potassium channel</strong> <strong>blockade, </strong>which would <strong>lengthen the action potential, </strong>contrary to what is shown in the graph.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to recognize the <strong>electrophysiologic profiles</strong> of <strong>different classes of antiarrhythmic drugs.</strong> <strong>Class IC</strong> <strong>antiarrhythmics like flecainide </strong>are characterized by their <strong>potent sodium channel-blocking effects</strong> with <strong>minimal impact </strong>on the <strong>duration of the action potential.</strong> Understanding these properties is important for the <strong>appropriate selection and use of antiarrhythmic drugs in clinical practice.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/image-3-1.jpg\" style=\"height:978px; width:600px\" /></span></span></span></p>",
    "correct_choice_id": 15247,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3821,
    "choices": [
      {
        "id": 15263,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These should be started at a very low dose and slowly titrated upwards</span></span></span></p>"
      },
      {
        "id": 15264,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carvedilol is the most widely used &beta; blocker</span></span></span></p>"
      },
      {
        "id": 15265,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These are drug of choice in acute decompensated heart failure</span></span></span></p>"
      },
      {
        "id": 15266,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These can reduce mortality in CHF patients</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT true about the use of &beta; blockers in CHF?</span></span></span></p>",
    "unique_key": "Q3002626",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407271,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) These are drug of choice in acute decompensated heart failure</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Beta blockers</strong> are not the drug of choice in<strong> acute decompensated heart failure.</strong> In fact, they are <strong>contraindicated</strong> in this condition due to <strong>their potential to worsen the hemodynamic status.</strong> In <strong>acute decompensated heart failure</strong>, the goal is to<strong> quickly improve cardiac</strong> <strong>output and relieve symptoms,</strong> and the<strong> negative inotropic effects of beta blockers </strong>can <strong>counteract this goal.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. These should be started at a very low dose and slowly titrated upwards:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is <strong>correct </strong>and a key principle in the <strong>chronic</strong> management of <strong>CHF</strong>. Beta blockers need to be started at<strong> low doses to avoid abrupt changes in cardiac function</strong> and allow for patient tolerance.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Carvedilol is the most widely used &beta; blocker:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>carvedilol </strong>is one of the commonly used <strong>beta blockers in CHF,</strong> saying it is &quot;<strong>the most widely used</strong>&quot; may <strong>not be true in all settings,</strong> as <strong>metoprolol and bisoprolol </strong>are<strong> also commonly prescribed.</strong> However, this statement is generally accepted in practice.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. These can reduce mortality in CHF patients:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is <strong>true</strong>. <strong>Beta blockers</strong> have been shown to<strong> decrease mortality in chronic</strong> <strong>CHF </strong>by <strong>improving left ventricular function</strong>, <strong>reducing arrhythmias, and limiting cardiac remodeling.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><strong><u> </u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Beta blockers</strong> should <strong>not</strong> be used as the <strong>drug of choice</strong> in <strong>acute decompensated heart failure</strong> but are essential for the management of<strong> chronic CHF</strong>, where they have been shown to <strong>reduce mortality and morbidity.</strong></span></span></span></p>",
    "correct_choice_id": 15265,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3823,
    "choices": [
      {
        "id": 15271,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin</span></span></span></p>"
      },
      {
        "id": 15272,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiloride</span></span></span></p>"
      },
      {
        "id": 15273,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cimetidine</span></span></span></p>"
      },
      {
        "id": 15274,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoconazole</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs can cause gynecomastia except:</span></span></span></p>",
    "unique_key": "Q1088630",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407272,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Amiloride</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiloride</strong> is a <strong>potassium-sparing diuretic</strong> that acts on the <strong>distal tubule of the nephron </strong>to <strong>inhibit sodium reabsorption</strong> and <strong>potassium excretion.</strong> It is<strong> not</strong> associated with the development <strong>of gynecomastia.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Digoxin:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Digoxin,</strong> a <strong>cardiac glycoside,</strong> has been associated with <strong>gynecomastia</strong> as a rare<strong> adverse effect, </strong>possibly due to its <strong>estrogen-like effects and alterations in hormone metabolism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Cimetidine:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cimetidine, a<strong> histamine H2 receptor antagonist</strong>, can cause <strong>gynecomastia </strong>by<strong> blocking androgen receptors </strong>and <strong>increasing prolactin secretion.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ketoconazole:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoconazole, <strong>an antifungal agent, </strong>can <strong>inhibit testosterone synthesis </strong>by <strong>blocking cytochrome P450</strong> enzymes, leading to <strong>elevated estrogen levels </strong>and resulting in <strong>gynecomastia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to<strong> recognize medications associated with the development of gynecomastia a</strong>s an adverse effect.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IMPORTANT DRUGS CAUSING GYNAECOMASTIA:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DI: DI</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">goxin</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">S: S</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">pironolactone</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C: C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">imetidine, <strong>K</strong>etoconazole</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">O: O</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">estrogens</span></span></span></p>",
    "correct_choice_id": 15272,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 23451,
    "choices": [
      {
        "id": 93768,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduce preload</span></span></span></p>"
      },
      {
        "id": 93769,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sildenafil may pronounce hypotension and should never be combined</span></span></span></p>"
      },
      {
        "id": 93770,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cause redistribution of coronary blood flow</span></span></span></p>"
      },
      {
        "id": 93771,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tolerance is most seen in sublingual administration of nitrates</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements about the Nitrates in Angina are true except?</span></span></span></p>",
    "unique_key": "Q4394017",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407273,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Tolerance is most seen in sublingual administration of nitrates</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tolerance to nitrates </strong>develops when they are continuously present in the <strong>bloodstream for prolonged periods</strong>. This is more common with<strong> oral, transdermal, or continuous intravenous infusion of nitrates, </strong>as well as with <strong>long-acting agent</strong>s, particularly those in <strong>sustained release formulations.</strong> In contrast, there is <strong>no</strong> significant <strong>development of tolerance</strong> when <strong>sublingual nitrates </strong>are<strong> used</strong> <strong>intermittently for acute attacks of angina.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Reduce preload:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>True</strong>. <strong>Nitrates predominantly dilate veins, </strong>leading to a <strong>reduction in preload,</strong> which <strong>decreases the amount</strong> of <strong>blood returning to the heart</strong>, thereby <strong>reducing the work the hear</strong>t has to <strong>do and the oxygen demand.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Sildenafil may pronounce hypotension and should never be combined:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>True.</strong> Combining<strong> nitrates with sildenafil </strong>can lead to dangerous potentiation of <strong>vasodilatory effects, </strong>resulting in <strong>severe hypotension,</strong> <strong>myocardial infarction, and even death.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Cause redistribution of coronary blood flow:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>True</strong>. Nitrates preferentially <strong>dilate larger</strong> <strong>conducting coronary arteries </strong>over <strong>arterioles</strong>, which may facilitate<strong> increased blood flow to ischemic areas of the heart</strong> in patients with<strong> angina.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the context of angina treatment, <strong>nitrates </strong>are known to <strong>reduce preload </strong>and can cause <strong>redistribution of coronary blood flow</strong>, but <strong>significant tolerance</strong> is <strong>not</strong> typically associated<strong> with intermittent sublingual administration. </strong>It is also critical to <strong>avoid the</strong> <strong>combination of nitrates with sildenafil </strong>due to the <strong>risk of severe hypotension.</strong></span></span></span></p>",
    "correct_choice_id": 93771,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3854,
    "choices": [
      {
        "id": 15395,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone </span></span></span></p>"
      },
      {
        "id": 15396,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sotalol</span></span></span></p>"
      },
      {
        "id": 15397,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine </span></span></span></p>"
      },
      {
        "id": 15398,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lignocaine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following antiarrhythmic drug is contraindicated in a patient with interstitial lung disease? </span></span></span></p>",
    "unique_key": "Q7298812",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407274,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Amiodarone</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiodarone</strong> is a<strong> class III antiarrhythmic agent </strong>that has a <strong>well-documented side effect profile, </strong>including <strong>pulmonary toxicity.</strong> The drug can <strong>cause pulmonary alveolitis and fibrosis</strong>, which are <strong>particularly serious </strong>and can be<strong> life-threatening</strong>. Because of its<strong> potential</strong> <strong>to exacerbate pulmonary conditions</strong>, it is <strong>contraindicated </strong>in patients with<strong> existing interstitial lung disease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Sotalol:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Sotalol is also a <strong>class III antiarrhythmic drug</strong> but <strong>does not </strong>carry the same risk for inducing <strong>pulmonary toxicity as</strong> <strong>amiodarone.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Quinidine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Quinidine is a<strong> class Ia antiarrhythmic drug</strong> and is <strong>not </strong>associated with<strong> interstitial lung disease</strong> as a side effect.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Lignocaine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Lignocaine (lidocaine) is a<strong> class Ib antiarrhythmic </strong>drug used mainly in <strong>acute settings for ventricular</strong> <strong>arrhythmias </strong>and <strong>does not</strong> have<strong> pulmonary toxicity akin to amiodarone.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiodarone,</strong> while effective as a <strong>broad-spectrum antiarrhythmic agent</strong>, is <strong>contraindicated in patients</strong> with <strong>interstitial lung disease</strong> because of its serious <strong>side effect of pulmonary alveolitis and fibrosis.</strong></span></span></span></p>",
    "correct_choice_id": 15395,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3856,
    "choices": [
      {
        "id": 15403,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranolazine </span></span></span></p>"
      },
      {
        "id": 15404,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trimetazidine</span></span></span></p>"
      },
      {
        "id": 15405,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ivabradine </span></span></span></p>"
      },
      {
        "id": 15406,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fasudil</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs block late inward sodium ion channels?</span></span></span></p>",
    "unique_key": "Q7657781",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407275,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Ranolazine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranolazine is known for its unique mechanism of action as a late inward sodium channel blocker. This property allows it to reduce the intracellular accumulation of sodium, which can reduce the calcium overload in cardiac cells through the sodium-calcium exchanger. By doing so, ranolazine helps to improve myocardial relaxation and decreases cardiac ischemia without significantly affecting the heart rate or blood pressure.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Trimetazidine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Trimetazidine acts as a partial fatty acid oxidation inhibitor, optimizing the energy metabolism of the heart during ischemia, but it does not block sodium channels.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ivabradine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ivabradine selectively inhibits the funny current (If) in the sinoatrial node, resulting in heart rate reduction, which can be beneficial in conditions like angina and heart failure, but it is not a sodium channel blocker.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Fasudil:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Fasudil is a Rho-kinase inhibitor with vasodilatory effects and does not block sodium channels.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranolazine is a late inward sodium channel blocker that can be used to treat chronic angina by improving myocardial relaxation and decreasing ischemia without major effects on heart rate or blood pressure.</span></span></span></p>",
    "correct_choice_id": 15403,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3693,
    "choices": [
      {
        "id": 14751,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anterior thigh</span></span></span></p>"
      },
      {
        "id": 14752,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lateral thigh</span></span></span></p>"
      },
      {
        "id": 14753,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Upper arm</span></span></p>"
      },
      {
        "id": 14754,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Around umbilicus</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following sites is least commonly preferred for insulin injection? </span></span></span></p>",
    "unique_key": "Q8388063",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407276,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D. Around umbilicus</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sites of Insulin Injection</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Insulin </strong>usually is <strong>injected</strong> into the <strong>subcutaneous tissues of the abdomen, buttock, anterior and lateral thigh or upper arm.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Absorption </strong>is variable in the area<strong> around the umbilicus, </strong>therefore this site is not recommended for insulin administration.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Absorption</strong> is usually <strong>most rapid from the abdominal wall,</strong> followed by the<strong> arm, buttock, and thigh.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">If a patient is willing to<strong> inject into the abdomen, injections</strong> can be <strong>rotated throughout the entire area, </strong>thereby <strong>eliminating the injection site </strong>as a cause of variability in the <strong>rate of absorption.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The <strong>abdomen currently</strong> is the preferred <strong>site of injection</strong> because<strong> insulin is absorbed 20&ndash;30% faster from that site</strong> than <strong>from the arm.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Rotation of insulin injection</strong> sites traditionally has been advocated to <strong>avoid lipohypertrophy or lipoatrophy, </strong>although these conditions are i<strong>nfrequent with current preparations of insulin.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Option A. Anterior thigh </strong>and<strong> B. Lateral thigh C. Upper arm:</strong> These areas are <strong>common for insulin injections</strong> and provide <strong>consistent</strong> <strong>absorption</strong>, although generally <strong>slower </strong>compared to the <strong>abdominal wall.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SITES OF INSULIN INJECTION</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture5.jpg\" style=\"height:385px; width:600px\" /></p>",
    "correct_choice_id": 14754,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3685,
    "choices": [
      {
        "id": 14719,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></span></span></p>"
      },
      {
        "id": 14720,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
      },
      {
        "id": 14721,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exenatide</span></span></span></p>"
      },
      {
        "id": 14722,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rosiglitazone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old patient with Type 2 diabetes mellitus is being evaluated for potential adjustments to their diabetes management plan. The patient&#39;s current regimen includes metformin and lifestyle modifications. However, recent glycemic control has been suboptimal, and the healthcare provider is considering adding an additional medication to enhance insulin secretion, aiming to achieve better glucose control. Which of the following antidiabetic drugs act by increasing the secretion of insulin, making it a suitable addition to this patient&#39;s diabetes management plan?</span></span></span></p>",
    "unique_key": "Q7165833",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407277,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Exenatide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exenatide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>glucagon-like peptide-1 (GLP-1) receptor agonist.</strong> It works by<strong> increasing insulin secretion </strong>in a glucose-dependent manner, meaning it stimulates <strong>insulin release when blood glucose levels are high.</strong> Additionally, <strong>exenatide slows gastric emptying, suppresses appetite, and inhibits inappropriate post-meal glucagon release,</strong> all of which contribute to<strong> lowering blood glucose</strong> levels. Because of its mechanism of <strong>enhancing insulin secretion</strong> and other <strong>beneficial effects on glucose control, exenatide</strong> is a suitable addition for a patient with<strong> Type 2 diabetes </strong>looking to <strong>improve glycemic control </strong>beyond what has been achieved <strong>with</strong> <strong>metformin and lifestyle modifications.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pramlintide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: It is an <strong>amylin analogu</strong>e that <strong>mimics the natural hormone amylin</strong>. Pramlintide <strong>slows gastric emptying,</strong> <strong>reduces postprandial glucagon secretion,</strong> and <strong>promotes satiety</strong>, leading to <strong>decreased caloric intake</strong>. However, it<strong> does not</strong> directly <strong>increase insulin secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a <strong>biguanide,</strong> which is already part of the patient&#39;s regimen. Metformin works mainly by <strong>decreasing</strong> <strong>hepatic glucose production </strong>and improving<strong> insulin sensitivity</strong> but <strong>does not</strong> <strong>increase insulin secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Rosiglitazone</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: It belongs to the <strong>thiazolidinedione</strong> class of drugs, which work by<strong> increasing insulin sensitivity</strong> rather than directly<strong> stimulating insulin secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ANTI-DIABETIC DRUGS THAT ACT BY INCREASING THE SECRETION OF INSULIN:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture4.jpg\" style=\"height:744px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 14721,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3957,
    "choices": [
      {
        "id": 15807,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raloxifene</span></span></span></p>"
      },
      {
        "id": 15808,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bisphosphonates</span></span></span></p>"
      },
      {
        "id": 15809,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teriparatide</span></span></span></p>"
      },
      {
        "id": 15810,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Denosumab</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given figure shows the mechanism of action of Drug Y in treatment of osteoporosis. Which of the following best represents drug Y?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture16.jpg\" style=\"height:381px; width:600px\" /></p>",
    "unique_key": "Q9213385",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407278,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Denosumab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The figure illustrates that <strong>Drug Y inhibits the binding of RANKL to RANK, </strong>which is crucial for the <strong>formation, function, and survival of</strong> <strong>osteoclasts. Denosumab is a monoclonal antibody </strong>designed to <strong>target RANKL</strong>, thereby preventing it from <strong>activating RANK on</strong> <strong>osteoclasts and their precursors</strong>. This<strong> inhibition</strong> effectively reduces the<strong> formation and activity of osteoclasts,</strong> leading to a<strong> decrease in bone resorption.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Raloxifene:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect&nbsp;</strong>for this mechanism.<strong> Raloxifene is a selective estrogen receptor modulator (SERM) </strong>that mimics <strong>estrogen&#39;s bone-protective effect</strong>s by <strong>reducing osteoclast activity,</strong> but it<strong> does not</strong> work by targeting the<strong> RANKL-RANK interaction.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Bisphosphonates:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Also<strong> incorrect. </strong>Bisphosphonates<strong> inhibit</strong> <strong>osteoclast-mediated bone resorption</strong> by inducing <strong>osteoclast</strong> <strong>apoptosis </strong>and interfering with the<strong> mevalonate pathway</strong>, not by RANKL inhibition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Teriparatide:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect&nbsp;</strong>for this illustration. <strong>Teriparatide,</strong> a recombinant form of <strong>parathyroid hormone</strong>, primarily works by <strong>stimulating osteoblasts</strong> to promote <strong>bone formation rather than inhibiting osteoclasts.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Denosumab</strong> is used in the treatment of <strong>osteoporosis by targeting the RANKL-RANK interaction</strong>, effectively <strong>inhibiting osteoclast</strong> formation and activity, thus <strong>decreasing bone resorption.</strong></span></span></span></p>",
    "correct_choice_id": 15810,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3725,
    "choices": [
      {
        "id": 14879,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sumatriptan</span></span></span></p>"
      },
      {
        "id": 14880,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bromocriptine</span></span></span></p>"
      },
      {
        "id": 14881,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ergotamine</span></span></span></p>"
      },
      {
        "id": 14882,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Allopurinol</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 22-year-old female, Neeta, presented to you with complaints of headache and vomiting for 2 months. She has amenorrhea, but the urine pregnancy test is negative. She also complained of secretion of milk from the breasts. A provisional diagnosis of hyperprolactinemia was made, and MRI was suggested. MRI confirmed the presence of a large pituitary adenoma. Neeta was advised surgery; however, she is not willing to undergo surgery. Which of the following medications is most likely to be prescribed to control her symptoms?</span></span></span></p>",
    "unique_key": "Q1682011",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407279,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Bromocriptine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bromocriptine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a<strong> dopamine agonist</strong> that is effective in the treatment of <strong>hyperprolactinemia, </strong>which is characterized by <strong>elevated</strong> <strong>levels of prolactin </strong>leading to symptoms such as<strong> amenorrhea, galactorrhea (secretion of milk from the breasts), headache, </strong>and in some cases,<strong> vision problems </strong>due to <strong>pituitary adenomas</strong>. Bromocriptine works by <strong>binding to dopamine D2 receptors </strong>in the pituitary gland, which<strong> inhibits the secretion of prolactin</strong>. In addition to <strong>lowering prolactin levels</strong>, bromocriptine can also <strong>reduce the size of</strong> <strong>prolactin-secreting pituitary adenomas</strong>, thus <strong>helping to alleviate </strong>symptoms associated with the<strong> tumor</strong>, including <strong>headaches and</strong> <strong>vision issues.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Sumatriptan</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Sumatriptan is a medication<strong> used to treat acute migraine headaches</strong>. It is a <strong>serotonin receptor agonist</strong> that causes<strong> vasoconstriction of cranial blood vessels.</strong> It is<strong> not </strong>used in the treatment of<strong> hyperprolactinemia or pituitary adenomas.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ergotamine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Ergotamine is<strong> used for </strong>the treatment of <strong>migraine headaches</strong>. It is an <strong>ergot alkaloid </strong>that causes <strong>vasoconstriction. </strong>It<strong> does not</strong> reduce<strong> prolactin levels or treat pituitary adenomas.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Allopurinol</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Allopurinol is used to <strong>decrease high blood uric acid levels</strong>, as seen in <strong>gout </strong>and certain types of <strong>kidney stones. </strong>It is not relevant to the treatment of hyperprolactinemia or pituitary adenomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bromocriptine</strong> is the appropriate pharmacological treatment for<strong> hyperprolactinemia </strong>caused by a<strong> pituitary adenoma</strong>, especially when surgery is not an option. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bromocriptine</strong> is the preferred<strong> choice</strong> due to its dual role in<strong> reducing prolactin levels and potentially decreasing the size of the</strong> <strong>adenoma</strong>, thus addressing<strong> both </strong>the <strong>hormonal imbalance and its physical cause.</strong> </span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> </span></span></span></p>",
    "correct_choice_id": 14880,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3751,
    "choices": [
      {
        "id": 14983,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liraglutide</span></span></span></p>"
      },
      {
        "id": 14984,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitagliptin</span></span></span></p>"
      },
      {
        "id": 14985,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Canagliflozin</span></span></span></p>"
      },
      {
        "id": 14986,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pioglitazone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">An obese diabetic patient was on metformin monotherapy, but his sugar levels were not well controlled. He is allergic to sulfa drugs and does not comply with injectable drugs. He has a history of pancreatitis, and family history of bladder carcinoma. In view of the raised glucose levels, you wish to add another anti-diabetic drug. Which one would you prefer? </span></span></span></p>",
    "unique_key": "Q7413394",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407280,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Canagliflozin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In this clinical scenario, the <strong>choice of an additional anti-diabetic drug </strong>must consider the patient&rsquo;s <strong>specific health background </strong>and preferences. <strong>Canagliflozin</strong>, a <strong>sodium-glucose cotransporter 2 (SGLT2) inhibitor,</strong> is the most appropriate option. This class of medication<strong> lowers blood sugar </strong>by causing the <strong>kidneys to remove sugar from the body</strong> through the <strong>urine.</strong> It is suitable because it <strong>does not</strong> involve <strong>injection and does</strong> <strong>not </strong>have a known association with<strong> increased risk of pancreatitis or bladder carcinoma.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Liraglutide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Not </strong>suitable as it is an<strong> injectable GLP-1 receptor agonist,</strong> and the patient has a<strong> non-compliance issue</strong> with injectable medications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Sitagliptin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A <strong>DPP-4 inhibitor,</strong> which has been associated with <strong>cases of pancreatitis</strong>, making it a <strong>less suitable </strong>option for a patient with a history of this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pioglitazone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A <strong>thiazolidinedione</strong> that has been associated with an i<strong>ncreased risk of bladder cancer</strong>, especially in individuals with a<strong> family history of the disease</strong>, thus <strong>contraindicating its use in this patient.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture10.jpg\" style=\"height:415px; width:1000px\" /><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture11.jpg\" style=\"height:519px; width:1000px\" /></p>",
    "correct_choice_id": 14985,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3658,
    "choices": [
      {
        "id": 14611,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypotensive state</span></span></span></p>"
      },
      {
        "id": 14612,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alcoholics</span></span></span></p>"
      },
      {
        "id": 14613,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal failure</span></span></span></p>"
      },
      {
        "id": 14614,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypokalemia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following are contraindications for the use of metformin except?</span></span></span></p>",
    "unique_key": "Q4570542",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407281,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Hypokalemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metformin is a biguanide </strong>class of antidiabetic medication primarily used for the management of<strong> Type 2 diabetes mellitus</strong>. It works by <strong>decreasing hepatic glucose production </strong>and <strong>improving insulin sensitivity. </strong>It can <strong>increase risk of lactic acidosis </strong>particularly in patients with<strong> liver disease, renal disease </strong>and those<strong> pre-disposed to hypoxia</strong>. While it has <strong>several contraindications, hypokalemia (low potassium levels) is not </strong>directly related to its<strong> use or its mechanism of action</strong>. Therefore, the presence of <strong>hypokalemia does not preclude the use of metformin</strong>, provided that the<strong> hypokalemia itself is managed appropriately.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hypotensive state</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While <strong>not a direct contraindication, </strong>caution is advised in conditions that may <strong>predispose patients to hypotension</strong>, as <strong>low perfusion </strong>may<strong> increase the risk of metformin </strong>induced <strong>lactic acidosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Alcoholics</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Chronic and excessive alcohol </strong>consumption is a <strong>contraindication for metformin </strong>use due to the<strong> increased risk of lactic acidosis</strong>, especially in cases of<strong> hepatic impairment and acute alcohol intoxication.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Renal failure</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Renal failure or significant <strong>renal impairment is a contraindication </strong>for the use of<strong> metformin </strong>due to the <strong>increased risk of accumulating metformin </strong>and subsequent<strong> lactic acidosis</strong>. Latest guidelines regarding use of<strong> metformin in renal dysfunction </strong>include:</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture1.jpg\" style=\"height:229px; width:1000px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Risk factors for metformin induced lactic acidosis</span></em></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatic failure </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal failure </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alcoholics</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metabolic acidosis</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elderly</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Conditions predisposing to hypoxia (Shock, CHF, Severe anemia, Major surgery etc.)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mnemonic:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">MET: MET</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">abolic</span><strong> </strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">acidosis</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">F: F</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ailure (Liver and Renal failure)</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">O R MIN: O</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">xygen&nbsp;</span><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">R</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">eaching the tissues is&nbsp;</span><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">MIN</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">imum (means hypoxia causing conditions)</span></span></span></p>",
    "correct_choice_id": 14614,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3655,
    "choices": [
      {
        "id": 14599,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin</span></span></span></p>"
      },
      {
        "id": 14600,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vildagliptin</span></span></span></p>"
      },
      {
        "id": 14601,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"color:black\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Exenatidie</span></span></span></span></p>"
      },
      {
        "id": 14602,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old hypertensive patient with stage 5 chronic kidney disease was diagnosed recently with Type 2 diabetes mellitus. He does not want to take injectable drugs. Which of the following oral hypoglycemic agents will be preferred in this patient that does not require any dose modification in renal failure?</span></span></span></p>",
    "unique_key": "Q8631194",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407282,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Linagliptin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Linagliptin </strong>is a <strong>dipeptidyl peptidase-4 (DPP-4) inhibitor </strong>that is preferred in patients with <strong>renal impairment</strong>, including those with <strong>stage 5 CKD</strong>, because it <strong>does not require dose adjustments</strong>. Linagliptin&#39;s pharmacokinetics are such that it is <strong>less dependent on renal excretion compared </strong>to <strong>other DPP-4 inhibitors, </strong>making it a <strong>safer </strong>option for patients with significant <strong>renal dysfunction</strong>. This characteristic allows for the management of<strong> Type 2 diabetes in patients with varying degrees of kidney disease </strong>without the need to modify the dose, thus simplifying<strong> treatment and reducing </strong>the <strong>risk of drug accumulation and adverse effects.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Vildagliptin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While<strong> vildagliptin </strong>is another<strong> DPP-4 inhibitor, </strong>it<strong> requires dose adjustments </strong>in patients with <strong>renal impairment</strong>, making it<strong> less ideal than linagliptin </strong>for patients with <strong>stage 5 CKD</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Exenatide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Exenatide </strong>is <strong>not </strong>an <strong>oral hypoglycemic agent </strong>but an <strong>injectable glucagon-like peptide-1 (GLP-1) receptor agonist. </strong>It also <strong>requires dose adjustments </strong>in patients with <strong>renal impairment </strong>and would<strong> not </strong>be suitable for a patient who prefers to avoid injectable drugs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Traditionally, <strong>metformin </strong>has been <strong>contraindicated in patients </strong>with significant<strong> renal impairment due to the risk of lactic acidosis</strong>. Although recent guidelines have provided<strong> more lenient criteria </strong>for its use in patients with <strong>moderate renal impairment</strong>, it is generally <strong>avoided in stage 5 CKD</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Linagliptin, a DPP-4 inhibitor, </strong>is a preferred <strong>oral hypoglycemic agent </strong>for patients with <strong>Type 2 diabetes and severe renal impairment</strong>, as it<strong> does not </strong>require dose adjustments in<strong> renal failure</strong>, simplifying <strong>diabetes management </strong>in this population.</span></span></span></p>",
    "correct_choice_id": 14599,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 4256,
    "choices": [
      {
        "id": 17001,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carcinoma of ovary</span></span></span></p>"
      },
      {
        "id": 17002,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometrial carcinoma</span></span></span></p>"
      },
      {
        "id": 17003,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breast carcinoma</span></span></span></p>"
      },
      {
        "id": 17004,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic myeloid leukemia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A lady who was treated for breast cancer is on long-term tamoxifen therapy as she is ER-positive. Drug tamoxifen can increase the risk for which of the following cancers?<strong> </strong></span></span></span></p>",
    "unique_key": "Q4932986",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407283,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Endometrial carcinoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tamoxifen </strong>was the<strong> first&nbsp;selective estrogen receptor modulator (SERM)&nbsp;</strong>to be introduced. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen is extensively used in the<strong> palliative treatment of breast cancer in postmenopausal women </strong>and is approved for<strong> chemoprevention of breast cancer</strong> in<strong> high-risk women. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen has <strong>estrogen agonistic action on bone and blood. Prevention </strong>of the expected <strong>loss of lumbar spine bone</strong> <strong>density </strong>and <strong>plasma lipid changes</strong> consistent with a <strong>reduction in the risk for atherosclerosis </strong>have also been reported in <strong>tamoxifen-treated patients </strong>following <strong>spontaneous or surgical menopause. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">However, this <strong>estrogen agonist activity on uterus</strong> may <strong>increase the risk of endometrial cancer.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a <strong>nonsteroidal agent</strong> that is given<strong> orally. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen has an initial <strong>half-life of 7&ndash;14 hours </strong>in circulation and is predominantly <strong>excreted by the liver. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Toremifene</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;is a <strong>structurally similar compound</strong> with very <strong>similar properties, indications, and toxicities.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Carcinoma of the ovary:</strong> There is<strong> no </strong>established link between <strong>tamoxifen use</strong> and an increased risk of ovarian cancer. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Breast carcinoma:</strong> <strong>Tamoxifen</strong> is actually used to<strong> reduce the risk of breast cancer</strong> recurrence. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Chronic myeloid leukemia:</strong> There is<strong> no</strong> evidence to suggest that<strong> tamoxifen increases the risk of developing leukemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">While<strong> tamoxifen</strong> is effective in <strong>treating and preventing breast cancer</strong> recurrence in<strong> ER-positive patients</strong> by <strong>acting as an estrogen</strong> <strong>antagonist on breast tissue, </strong>its <strong>agonistic effects on the uterus</strong> can <strong>increase </strong>the risk of<strong> endometrial carcinoma, </strong>necessitating <strong>careful</strong> <strong>monitoring and evaluation during therapy.</strong></span></span></span></p>",
    "correct_choice_id": 17002,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3682,
    "choices": [
      {
        "id": 14707,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carbimazole</span></span></span></p>"
      },
      {
        "id": 14708,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lugol&rsquo;s iodine</span></span></span></p>"
      },
      {
        "id": 14709,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propylthiouracil</span></span></span></p>"
      },
      {
        "id": 14710,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methimazole</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old patient diagnosed with Graves&#39; disease is under consideration for antithyroid therapy. The patient has a history of atrial fibrillation and is currently on beta-blockers. Given the patient&#39;s clinical profile and the need to rapidly achieve euthyroidism while minimizing cardiac complications, the healthcare provider is exploring antithyroid medications that can not only reduce thyroid hormone production but also inhibit the peripheral conversion of thyroxine (T4) to the more active triiodothyronine (T3). Which of the following antithyroid medications can inhibit the peripheral conversion of T4 to T3?</span></span></span></p>",
    "unique_key": "Q6364365",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407284,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Propylthiouracil</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Propylthiouracil (PTU) </strong>is an <strong>antithyroid </strong>medication that<strong> not </strong>only <strong>inhibits thyroid hormone synthesis </strong>but also has the unique ability among <strong>antithyroid drugs to inhibit the peripheral conversion of thyroxine (T4) </strong>to the <strong>more active form</strong>, <strong>triiodothyronine (T3). </strong>This <strong>dual action </strong>can be particularly beneficial in managing <strong>hyperthyroidism </strong>in patients where <strong>rapid control of thyroid hormone effects </strong>is crucial, such as those with <strong>cardiac complications like atrial fibrillation. </strong>PTU&#39;s ability to<strong> reduce T3 levels </strong>can lead to a <strong>quicker normalization of thyroid hormone effects </strong>on the<strong> heart and other organs.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Carbimazole</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Carbimazole is a<strong> pro-drug </strong>that is<strong> converted to methimazole in the body</strong>. It <strong>inhibits thyroid hormone synthesis </strong>but <strong>does not </strong>significantly <strong>inhibit the peripheral conversion of T4 to T3.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Lugol&rsquo;s iodine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Lugol&#39;s iodine can quickly<strong> reduce the size and vascularity of the thyroid gland </strong>and <strong>inhibit </strong>the release of <strong>thyroid hormones</strong>, but it does not have a direct inhibitory effect on the peripheral conversion of T4 to T3.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Methimazole</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Methimazole<strong> inhibits thyroid hormone synthesis </strong>by blocking the<strong> iodination of tyrosine </strong>residues in <strong>thyroglobulin</strong>. Like<strong> carbimazole</strong>, it<strong> does not </strong>significantly <strong>inhibit the peripheral conversion of T4 to T3.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture3.jpg\" style=\"height:562px; width:1000px\" /></span></span></u></strong></p>",
    "correct_choice_id": 14709,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3700,
    "choices": [
      {
        "id": 14779,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Milnacipran</span></span></span></p>"
      },
      {
        "id": 14780,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teriparatide</span></span></span></p>"
      },
      {
        "id": 14781,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Strontium ranelate</span></span></span></p>"
      },
      {
        "id": 14782,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Denosumab</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs are used in treatment of osteoporosis except.</span></span></span></p>",
    "unique_key": "Q9494581",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407285,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Milnacipran</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Milnacipran</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is not used in the treatment of <strong>osteoporosis</strong>. It is a<strong> serotonin&ndash;norepinephrine reuptake inhibitor (SNRI)</strong> primarily used in the management of <strong>fibromyalgia and depression.</strong> It has <strong>no role</strong> in the management or treatment of <strong>osteoporosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Teriparatide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Teriparatide is a <strong>recombinant form of parathyroid hormone</strong> used in the treatment of<strong> osteoporosis.</strong> It stimulates<strong> new bone formation </strong>by acting on <strong>osteoblasts</strong>, making it effective in <strong>reducing the risk of fractures </strong>in patients with <strong>osteoporosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Strontium ranelate</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Strontium ranelate is a medication <strong>used to treat severe osteoporosis in postmenopausal women</strong> and <strong>men at high risk of fractures</strong>. It works by simultaneously <strong>decreasing bone resorption and increasing bone formation.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Denosumab</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Denosumab is a <strong>monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-B</strong> <strong>Ligand)</strong>, a protein that<strong> acts</strong> as the <strong>primary signal for bone removal</strong>. <strong>By inhibiting RANKL,</strong> denosumab <strong>decreases bone resorption and</strong> <strong>increases bone mass and strength</strong> in patients with osteoporosis.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs Used for Osteoporosis </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture6.jpg\" style=\"height:226px; width:1000px\" /></p>",
    "correct_choice_id": 14779,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3729,
    "choices": [
      {
        "id": 14895,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glucagonoma</span></span></span></p>"
      },
      {
        "id": 14896,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulinoma</span></span></span></p>"
      },
      {
        "id": 14897,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carcinoid syndrome</span></span></span></p>"
      },
      {
        "id": 14898,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glioma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Octreotide is used in all except? </span></span></span></p>",
    "unique_key": "Q5738935",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407286,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Glioma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glioma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> refers to a type of<strong> tumor</strong> that arises from<strong> glial cells</strong> in <strong>the brain or spinal cord. Octreotide,</strong> a<strong> somatostatin analogue, </strong>is <strong>not</strong> used in the treatment of <strong>gliomas. Octreotide&#39;</strong>s mechanism of action involves <strong>mimicking natural somatostatin</strong> to<strong> inhibit the secretion</strong> of several hormones, including <strong>growth hormone, glucagon, and insulin, </strong>making it useful in conditions related to<strong> excessive</strong> <strong>hormone secretion,</strong> but i<strong>t does not </strong>have a therapeutic role in the treatment of <strong>gliomas,</strong> which are <strong>primary brain or spinal cord</strong> <strong>tumors</strong>. The <strong>drug of choice</strong> for <strong>glioma is temozolomide.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Glucagonoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Octreotide</strong> is used in the management of <strong>glucagonoma,</strong> a rare type of <strong>pancreatic neuroendocrine tumor</strong> that <strong>secretes excessive amounts of glucagon. </strong>Octreotide helps in controlling symptoms by <strong>inhibiting glucagon secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Insulinoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Although <strong>insulinomas produce excessive insulin,</strong> <strong>octreotide</strong> can sometimes be used in the management of these tumors to<strong> help control hypoglycemia</strong>, particularly in patients with <strong>metastatic disease </strong>or those who are <strong>not candidates for</strong> <strong>surgery.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Carcinoid syndrome</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Octreotide </strong>is effectively used in the treatment of<strong> carcinoid syndrome</strong>, which is characterized by <strong>flushing, diarrhea, and wheezing </strong>due to the<strong> secretion of serotonin </strong>and other<strong> vasoactive substances</strong> by <strong>carcinoid tumors.</strong> <strong>Octreotide</strong> helps in reducing these symptoms by <strong>inhibiting the secretion of these substances.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uses of Octreotide</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture8.jpg\" style=\"height:228px; width:1000px\" /></p>",
    "correct_choice_id": 14898,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3733,
    "choices": [
      {
        "id": 14911,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is effective orally.</span></span></span></p>"
      },
      {
        "id": 14912,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used for the treatment of acromegaly.</span></span></span></p>"
      },
      {
        "id": 14913,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be used for the management of secretory Diarrhea.</span></span></span></p>"
      },
      {
        "id": 14914,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be used in portal hypertension.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements about octreotide are true except.</span></span></span></p>",
    "unique_key": "Q6616879",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407287,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. It is effective orally.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is effective orally</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is<strong> not true</strong> about<strong> octreotide</strong>. <strong>Octreotide is a synthetic analogue of somatostatin </strong>and its therapeutic effects are primarily through <strong>parenteral route</strong>s, such as <strong>subcutaneous or intravenous injections</strong>. The<strong> oral bioavailability of octreotide is</strong> <strong>extremely low</strong> due to its<strong> rapid degradation</strong> in the g<strong>astrointestinal tract</strong> and its <strong>inability to be effectively absorbed </strong>when taken by <strong>mouth</strong>. Therefore, it is<strong> not used or effective in oral form for clinical purposes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <em>Drugs ending with <strong>&lsquo;tide&rsquo; are peptides</strong> and are <strong>not effective orally </strong></em></span><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>because</strong>, the <strong>presence of peptidases (like pepsin, trypsin </strong>etc.) in the GIT&nbsp; will <strong>make these inactive.</strong></span></em></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. It is used for the treatment of acromegaly</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This statement is <strong>true</strong>. <strong>Octreotide</strong> is used in the<strong> treatment of acromegaly,</strong> a condition characterized by<strong> excessive growth hormone production, leading to enlarged</strong> features. <strong>Octreotide </strong>helps by <strong>inhibiting</strong> <strong>growth hormone secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. It can be used for the management of secretory Diarrhea</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is also<strong> true.</strong> Octreotide can manage <strong>secretory diarrhea,</strong> including that<strong> caused by certain tumors (like carcinoid tumors or VIPomas),</strong> by <strong>inhibiting the secretion</strong> of various gastrointestinal <strong>hormones and substances.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. It can be used in portal hypertension</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>True.</strong> Octreotide is used in the management of <strong>portal hypertension, </strong>particularly to <strong>control variceal bleeding, </strong>by <strong>reducing blood flow</strong> to the<strong> gastrointestinal tract</strong> and<strong> lowering portal vein pressure.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While<strong> octreotide</strong> is a valuable medication in the management of <strong>acromegaly, secretory diarrhea, and portal hypertension,</strong> it must be administered through<strong> parenteral routes</strong> due to its<strong> poor oral bioavailability. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> - You can remember this fact from the name of the drug. If the <strong>name of a drug ends with &lsquo;tide&rsquo;,</strong> it is a <strong>peptide and peptides</strong> <strong>cannot be given orally</strong> because, the <strong>presence of peptidases (like pepsin, trypsin etc.)</strong> will make these <strong>inactive.</strong></span></span></span></p>",
    "correct_choice_id": 14911,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3940,
    "choices": [
      {
        "id": 15739,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">GnRH agonist</span></span></span></p>"
      },
      {
        "id": 15740,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen antagonist</span></span></span></p>"
      },
      {
        "id": 15741,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective estrogen receptor modulator</span></span></span></p>"
      },
      {
        "id": 15742,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective progesterone receptor modulator</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ulipristal is a relatively new drug being used by gynecologists. It acts as a?</span></span></span></p>",
    "unique_key": "Q4852686",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407288,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Selective progesterone receptor modulator</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ulipristal</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> acts as a <strong>Selective Progesterone Receptor Modulator (SPRM)</strong>. It is used in gynaecology for specific conditions such as the <strong>emergency contraception (30 mg single dose</strong> can be used up to <strong>120 hours of unprotected intercourse)</strong> and the treatment of <strong>moderate to severe symptoms of uterine fibroids</strong> in<strong> premenopausal women.</strong> As an<strong> SPRM,</strong> <strong>ulipristal</strong> works by <strong>modulating the</strong> <strong>progesterone receptors in the body,</strong> which can have <strong>both agonistic and antagonistic effects </strong>depending on the tissue. This action allows it to<strong> alter the endometrium,</strong> i<strong>nhibit or delay ovulation, </strong>and <strong>reduce the size </strong>and <strong>symptoms of uterine fibroids</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. GnRH agonist</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: GnRH agonists work by<strong> initially stimulating and then downregulating the production of gonadotropins (LH</strong> <strong>and FSH)</strong>, leading to a<strong> decrease in estrogen and testosterone production</strong>. Examples include <strong>leuprolide and goserelin</strong>. <strong>Ulipristal does</strong> <strong>not act </strong>through this<strong> mechanism.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Androgen antagonist</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Androgen antagonists <strong>block the effects of androgens (male hormones) at their receptor sites</strong>. They are used in conditions like<strong> prostate cancer and hirsutism in women.</strong> Ulipristal does not function as an androgen antagonist.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Selective estrogen receptor modulator</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: SERMs, such as<strong> tamoxifen or raloxifene,</strong> act on <strong>estrogen receptors</strong>, having <strong>agonistic or antagonistic effects depending on the target tissue</strong>. <strong>Ulipristal, </strong>however, specifically <strong>modulates progesterone receptors,</strong> <strong>not</strong> <strong>estrogen receptors.</strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective:</u></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ulipristal </strong>is a<strong> selective progesterone receptor modulator (SPRM)</strong> used in<strong> gynecology for emergency contraception </strong>and the treatment of<strong> uterine fibroids</strong>. Its unique <strong>action on progesterone receptors </strong>allows for <strong>versatile therapeutic effects</strong> in <strong>reproductive</strong> <strong>health.</strong></span></span></span></p>",
    "correct_choice_id": 15742,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3941,
    "choices": [
      {
        "id": 15743,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">To be given an empty stomach with a full glass of water.</span></span></span></p>"
      },
      {
        "id": 15744,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Must be taken along with food.</span></span></span></p>"
      },
      {
        "id": 15745,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Should be stopped if features of gastritis develop.</span></span></span></p>"
      },
      {
        "id": 15746,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Should be stopped if bone pains occur.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">What are the appropriate instructions to be given while prescribing bisphosphonates to a patient? </span></span></span></p>",
    "unique_key": "Q4977515",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407289,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. To be given empty stomach with a glass of water</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bisphosphonates</strong> should be taken on an <strong>empty stomach with a full glass of water </strong>to enhance <strong>absorption</strong>. Patients are advised to remain <strong>upright (sitting or standing) for at least 30 to 60 minutes </strong>after taking the medication. This precaution <strong>helps to prevent</strong> <strong>esophageal irritation</strong> and <strong>ensure the drug moves quickly to the stomach, reducing the risk of gastroesophageal reflux </strong>and <strong>esophagitis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Must be taken along with food</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This instruction is<strong> incorrect</strong> because<strong> food</strong> significantly <strong>decreases the absorption of</strong> <strong>bisphosphonates.</strong> They <strong>should be taken</strong> on an<strong> empty stomach.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Should be stopped if features of gastritis develop</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While patients should report any<strong> severe gastrointestinal symptoms</strong> to their <strong>healthcare provider,</strong> the<strong> decision to stop </strong>the medication should be made<strong> by the physician.</strong> Management strategies may include evaluating the patient&#39;s condition, considering an <strong>alternative bisphosphonate formulation (e.g., intravenous),</strong> or<strong> addressing</strong> the <strong>gastritis </strong>while<strong> continuing treatment as necessary.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Should be stopped if bone pains occur</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bone pain can be a <strong>side effect of bisphosphonates, </strong>but patients <strong>should consult</strong> their <strong>healthcare provider </strong>before <strong>stopping the medication</strong>. The provider may assess the <strong>cause of bone pain</strong> and consider <strong>alternative</strong> <strong>treatments or supportive</strong> measures rather than<strong> immediately discontinuing the bisphosphonate.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When prescribing<strong> bisphosphonates,</strong> it is<strong> crucial to instruct patients</strong> to take the medication on an<strong> empty stomach </strong>with <strong>plenty of</strong> <strong>water </strong>and to remain<strong> upright for</strong> at<strong> least 30 to 60 minutes</strong> afterward to <strong>prevent gastrointestinal complications</strong> and ensure <strong>optimal</strong> <strong>absorption of the drug.</strong></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span> </span></span></span></p>",
    "correct_choice_id": 15743,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3753,
    "choices": [
      {
        "id": 14991,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
      },
      {
        "id": 14992,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin</span></span></span></p>"
      },
      {
        "id": 14993,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol</span></span></span></p>"
      },
      {
        "id": 14994,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient of diabetes mellitus and hypertension is admitted in the hospital with features of sepsis and there is increase in serum creatinine levels. Which of the following drugs should be stopped? </span></span></span></p>",
    "unique_key": "Q8843992",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407290,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Metformin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> should be<strong> stopped </strong>in this patient&rsquo;s case <strong>due to the development of sepsis and the increase in serum creatinine levels, </strong>which<strong> indicate an acute deterioration in renal function</strong>. Metformin is<strong> contraindicated </strong>in conditions that <strong>can impair renal function or lead to renal failure </strong>because of the <strong>risk of lactic acidosis</strong>, a rare but<strong> serious complication a</strong>ssociated with <strong>metformin accumulation </strong>in the body. In the setting of sepsis, which can further compromise <strong>renal function and increase the risk of lactic acidosis</strong>, <strong>discontinuation of metformin</strong> is advised until the patient&rsquo;s <strong>renal function stabilizes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Insulin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Insulin may still be needed to manage the patient&#39;<strong>s blood glucose levels, </strong>especially in the<strong> stress of sepsis</strong>, which can cause<strong> hyperglycemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Metoprolol</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: It is a<strong> lipid soluble beta-blocker </strong>used to manage<strong> hypertension </strong>and other <strong>cardiovascular conditions</strong>. It is <strong>safe </strong>in <strong>renal failure</strong>.<strong> Beta blockers</strong> which should be <strong>avoided in renal failure are atenolol, nadolol and sotalol (ANS) </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Linagliptin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A<strong> DPP-4 inhibitor </strong>used in the management of<strong> type 2 diabetes. </strong>It is considered safe in patients with <strong>renal impairment </strong>unlike other drugs in this group. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with <strong>diabetes and renal impairment, </strong>especially in <strong>acute settings such as sepsis,</strong><em> <strong>metformin </strong></em>should be discontinued to prevent the <strong>risk of lactic acidosis.</strong> It is important to<strong> monitor renal function </strong>closely and adjust medication as needed based on the patient&rsquo;s <strong>current health status.</strong></span></span></p>",
    "correct_choice_id": 14991,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3955,
    "choices": [
      {
        "id": 15799,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neutral protamine Hagedorn</span></span></span></p>"
      },
      {
        "id": 15800,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin glulisine</span></span></span></p>"
      },
      {
        "id": 15801,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin glargine</span></span></span></p>"
      },
      {
        "id": 15802,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lente insulin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Longest acting insulin among the following is?</span></span></span></p>",
    "unique_key": "Q8610995",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407291,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Insulin glargine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin glargine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is the<strong> longest-acting insulin </strong>among the options listed. It is a <strong>long-acting basal insulin </strong>analog with a <strong>duration of action</strong> that can <strong>last up to 24 hours,</strong> providing a<strong> steady level of insulin </strong>that mimics the <strong>natural basal secretion</strong> by the <strong>pancreas.</strong> <strong>Insulin glargine</strong> is designed to <strong>help control blood sugar levels throughout the day and night, </strong>making it particularly useful for managing<strong> basal insulin requirements in individuals with diabetes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Overall<strong> longest acting insulin is insulin degludec.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Neutral protamine Hagedorn (NPH)</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: NPH insulin is an <strong>intermediate-acting insulin </strong>with a <strong>duration of action </strong>that typically ranges from <strong>16 to 24 hours</strong>. While it does provide<strong> longer coverage than short-acting insulins,</strong> it does not last as long as insulin glargine.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Insulin glulisine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Insulin glulisine is a<strong> rapid-acting insulin analog </strong>with a <strong>quick onset of action</strong> (approximately <strong>15 minutes</strong>) and a <strong>shorter duration of action (3 to 5 hours)</strong>, making it <strong>well-suited for controlling blood sugar levels during meals.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Lente insulin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Lente insulin is an <strong>intermediate-acting insulin</strong> with a <strong>duration of action</strong> similar to <strong>NPH insulin.</strong> It is<strong> not</strong> as <strong>long-acting as insulin glargine.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">INSULIN PREPARATIONS</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture15.jpg\" style=\"height:467px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 15801,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3962,
    "choices": [
      {
        "id": 15827,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liothyronine</span></span></span></p>"
      },
      {
        "id": 15828,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">L-Thyroxine</span></span></span></p>"
      },
      {
        "id": 15829,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carbimazole</span></span></span></p>"
      },
      {
        "id": 15830,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Steroids</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presented with swelling in the neck as shown in figure. She also complained of decreased appetite, fatigue, cold intolerance, and menstrual irregularities. She gained 10 kg weight in the last 4-5 months. Thyroid function tests showed normal T4 levels but elevated TSH levels. The patient should be treated with. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture22.jpg\" style=\"height:227px; width:300px\" /></p>",
    "unique_key": "Q3132953",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407292,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. L-Thyroxine </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s clinical presentation and laboratory findings suggest hypothyroidism, characterized by swelling in the neck (likely indicating goitre), symptoms of decreased appetite, fatigue, cold intolerance, menstrual irregularities, weight gain, normal T4 levels, but elevated TSH levels. The appropriate treatment in this case would be L-thyroxine.</span></span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">L-Thyroxine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> (levothyroxine) is the standard treatment for hypothyroidism. It is a synthetic form of thyroxine (T4), the hormone that is deficient in hypothyroidism. Supplementation with L-Thyroxine helps to normalize thyroid hormone levels, thereby alleviating</strong> the symptoms of <strong>hypothyroidism</strong>, including those described for the <strong>patient. </strong>The<strong> goal of treatmen</strong>t is to <strong>normalize the patient&#39;s TSH levels and resolve symptoms.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Liothyronine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Liothyronine is a<strong> synthetic form of triiodothyronine (T3)</strong>. While it can be <strong>used </strong>in certain <strong>specific situations,</strong> such as in<strong> combination therapy with levothyroxine </strong>for some patients,<strong> L-Thyroxine </strong>remains the <strong>primary treatment</strong> for <strong>hypothyroidism</strong> due to its<strong> stability, longer half-life, and more consistent serum levels.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Carbimazole</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Carbimazole is used to <strong>treat hyperthyroidism, </strong>not hypothyroidism. It works by <strong>inhibiting the synthesis of</strong> <strong>thyroid hormones,</strong> which would be <strong>contraindicated in a patient </strong>already showing <strong>signs of low thyroid hormone activity.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Steroids</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Steroids are <strong>not a primary treatment for primary hypothyroidism</strong>. They can be used in <strong>specific cases of</strong> t<strong>hyroiditis</strong> where<strong> inflammation is a significant </strong>component, but they would <strong>not be the first choice i</strong>n typical hypothyroidism treatment.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with <strong>hypothyroidism </strong>indicated by symptoms of<strong> thyroid hormone deficiency </strong>and<strong> elevated TSH levels</strong> with <strong>normal T4, L-Thyroxine </strong>is the appropriate <strong>treatment </strong>to<strong> normalize thyroid function and alleviate symptoms.</strong></span></span></p>",
    "correct_choice_id": 15828,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3965,
    "choices": [
      {
        "id": 15839,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitagliptin</span></span></span></p>"
      },
      {
        "id": 15840,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dapagliflozin</span></span></span></p>"
      },
      {
        "id": 15841,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin</span></span></span></p>"
      },
      {
        "id": 15842,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old female with a history of type 2 diabetes mellitus presents to the clinic with complaints of recurrent urinary tract infections (UTIs) over the past few months. She reports symptoms of urgency, frequency, and dysuria. Her diabetes has been managed with an antidiabetic medication added to her regimen about 6 months ago, around the time the UTIs started becoming more frequent. Her medical history is otherwise unremarkable, and she is not on any other new medications. Which of the following drugs in her treatment regimen is most likely implicated in causing this adverse effect?</span></span></span></p>",
    "unique_key": "Q7541641",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407293,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Dapagliflozin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dapagliflozin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a<strong> Sodium-glucose cotransporter 2 (SGLT2) inhibitor</strong> used in the management of<strong> type 2 diabetes mellitus. </strong>SGLT2 <strong>inhibitors</strong> work by<strong> preventing glucose reabsorption in the kidneys,</strong> leading to the <strong>excretion of glucose in the urine</strong>. This mechanism can <strong>increase the risk of urinary tract infections (UTIs) </strong>due to the<strong> higher glucose</strong> content in the<strong> urine,</strong> which can provide a<strong> medium</strong> <strong>for bacterial growth</strong>. The temporal association between the<strong> start of the medication and the onset of recurrent UTIs</strong> in this patient suggests that <strong>dapagliflozin </strong>is the<strong> most</strong> probable <strong>antidiabetic drug </strong>implicated in causing this<strong> adverse effect.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Sitagliptin&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">and <strong>C. Linagliptin</strong>: Both are <strong>Dipeptidyl peptidase-4 (DPP-4) inhibitors. </strong>They work by <strong>increasing incretin levels,</strong> which<strong> inhibit glucagon release and increase insulin secretion</strong>. DPP-4 inhibitors are <strong>not </strong>commonly associated with an <strong>increased risk</strong> <strong>of UTIs.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pramlintide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: An<strong> amylin analogue </strong>used in addition to <strong>insulin therapy in type 1 and type 2 diabetes</strong> to improve <strong>glycemic</strong> control.<strong> Pramlintide </strong>is <strong>not </strong>associated with an<strong> increased risk of UTIs.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Dapagliflozin is an SGLT2 inhibitor </strong>that can<strong> increase the risk of urinary tract infections</strong> due to <strong>glucosuria,</strong> which can encourage <strong>bacterial growth </strong>in the urinary tract. <strong>Important points about SGLT2 Inhibitors are -</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">These<strong> reduce reabsorption of filtered glucose</strong> and <strong>lowers the renal threshold for glucose</strong>, and thereby <strong>increases urinary</strong> <strong>glucose excretion.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">These are <strong>NOT </strong>recommended for patients with <strong>type 1 diabetes mellitus</strong> or for the treatment of <strong>diabetic ketoacidosis.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">These should<strong> NOT</strong> be initiated in patients with an&nbsp;<strong>eGFR less than 60 mL/min/1 .73 m<sup>2.</sup></strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Adverse Effects:</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Increases </strong>the risk of <strong>genital mycotic infections.</strong></span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Urinary tract infections.</strong></span></span></span></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypotension.</span></span></span></strong></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">I<strong>mpairment in Renal Function.</strong></span></span></span></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increases in Low-Density Lipoprotein Cholesterol (LDL-C)</span></span></span></strong></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>",
    "correct_choice_id": 15840,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 4094,
    "choices": [
      {
        "id": 16355,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometriosis</span></span></span></p>"
      },
      {
        "id": 16356,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Male infertility</span></span></span></p>"
      },
      {
        "id": 16357,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Precocious puberty</span></span></span></p>"
      },
      {
        "id": 16358,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prostatic carcinoma</span></span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-pulsatile administration of GnRH agonist can be used in all of the following conditions except.</span></span></p>",
    "unique_key": "Q2016109",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407294,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Male infertility </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">For treatment of <strong>male infertility,</strong> <strong>GnRH agonists</strong> need to be given in <strong>pulsatile manner. </strong>For all other conditions given in the options, <strong>GnRH agonists </strong>are administered in a <strong>non-pulsatile continuous fashion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gonadotropin-Releasing Hormone (GnRH) and Its Analogs</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>GnRH is a decapeptide</strong> that stimulates <strong>gonadotropin release</strong> when it is secreted in a <strong>pulsatile pattern by the</strong> <strong>hypothalamus.&nbsp;</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Leuprolide&nbsp;</strong>was the <strong>first long-acting GnRH agonist. Other</strong> long-acting GnRH agonists include<strong>&nbsp;goserelin,&nbsp;histarelin,</strong> <strong>busurelin,&nbsp;nafarelin,&nbsp;and&nbsp;triptorelin.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Steady dosing (non-pulsatile) with these GnRH agonists inhibits gonadotropin </strong>release by <strong>downregulating GnRH</strong> receptors in th<strong>e pituitary cells </strong>that normally release <strong>gonadotropins. </strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulsatile administration of GnRH agonists is used for:</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypogonadotropic hypogonadism.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infertility in both males (oligozoospermia) and females (anovulatory infertility)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Delayed puberty</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Continuous GnRH agonist treatment is used:</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">To suppress <strong>endogenous gonadotropin secretion </strong>in <strong>women</strong> undergoing<strong> ovulation induction with gonadotropin</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In women with <strong>gynecologic disorders</strong> that benefit from <strong>ovarian suppression (e.g., endometriosis, uterine leiomyomata)</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In men with <strong>advanced prostate cancer</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In children with <strong>central precocious puberty.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> first few days</strong> of <strong>continuous administration </strong>can<strong> temporarily exacerbate </strong>the condition. This is known as<strong> flare up reaction.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Endometriosis</strong>: <strong>Continuous GnRH agonist</strong> treatment can <strong>suppress ovarian function </strong>and is beneficial in conditions like <strong>endometriosis. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Precocious Puberty</strong>:<strong> GnRH agonists</strong> are used to suppress<strong> premature gonadotropin secretion</strong> in children with <strong>central</strong> <strong>precocious puberty. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Prostatic Carcinoma</strong>: In men with <strong>advanced prostate cancer,</strong> continuous<strong> GnRH agonist </strong>treatment is used to<strong> suppress</strong> <strong>androgen production.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Non-pulsatile administration of GnRH agonists</strong> is utilized for conditions requiring <strong>suppression of gonadotropin secretion</strong>, such as <strong>endometriosis, prostatic carcinoma, and precocious puberty, </strong>but<strong> not </strong>for <strong>male infertility</strong>, which requires <strong>pulsatile treatment</strong> to stimulate <strong>gonadotropin release.</strong></span></span></span></span></span></span></p>",
    "correct_choice_id": 16356,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 4096,
    "choices": [
      {
        "id": 16363,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></span></span></p>"
      },
      {
        "id": 16364,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
      },
      {
        "id": 16365,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitagliptin</span></span></span></p>"
      },
      {
        "id": 16366,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glipizide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drug is approved for treatment of type 1 as well as type 2 diabetes mellitus?</span></span></span></p>",
    "unique_key": "Q8022585",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407295,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Pramlintide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is an <strong>amylin analogue</strong> approved for use in<strong> both type 1 and type 2 diabetes mellitus.</strong> It is used as an <strong>adjunct treatment</strong> for patients who are already using <strong>insulin </strong>but have <strong>not achieved</strong> desired <strong>glucose control. Pramlintide </strong>works by<strong> mimicking the</strong> <strong>actions of amylin&mdash;a hormone </strong>that is<strong> co-secreted </strong>with<strong> insulin from pancreatic &beta;-cells</strong>&mdash;thereby <strong>slowing gastric emptying, promoting</strong> <strong>satiety,</strong> and<strong> preventing postprandial spikes in blood glucose levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Primarily used in the treatment of <strong>type 2 diabetes mellitus,</strong> metformin is a<strong> biguanide </strong>that <strong>reduces hepatic</strong> <strong>glucose production and improves insulin sensitivity. </strong>It is <strong>not used </strong>in the treatment of <strong>type 1 diabetes </strong>because type 1 diabetes involves <strong>insulin deficiency, </strong>and<strong> metformin does not replace insulin.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Sitagliptin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A <strong>dipeptidyl peptidase-4 (DPP-4) inhibitor</strong> used in the treatment of <strong>type 2 diabetes</strong>. It works by<strong> increasing</strong> <strong>incretin levels</strong>, which <strong>inhibit glucagon release and increase insulin secretion </strong>in a <strong>glucose-dependent</strong> manner.<strong> Sitagliptin </strong>is <strong>not</strong> approved for use in<strong> type 1 diabetes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Glipizide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A <strong>sulfonylurea</strong> used in the treatment of <strong>type 2 diabetes</strong>. It stimulates the <strong>release of insulin from pancreatic &beta;-cells</strong>. Because individuals with <strong>type 1 diabetes</strong> have little to <strong>no insulin production, sulfonylureas like glipizide </strong>are not effective for<strong> type 1 diabetes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Pramlintide</strong> is approved for<strong> both type 1 and type 2 diabetes </strong>as an <strong>adjunct to insulin therapy </strong>due to its role in <strong>modulating gastric</strong> <strong>emptying and blood glucose levels post meals.</strong></span></span> <span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span></span></span></span></p>",
    "correct_choice_id": 16363,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 4113,
    "choices": [
      {
        "id": 16431,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin:&nbsp; Treatment of diabetes insipidus.</span></span></span></p>"
      },
      {
        "id": 16432,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Octreotide:&nbsp; Treatment of bleeding esophageal varices.</span></span></span></p>"
      },
      {
        "id": 16433,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oxytocin:&nbsp; Induction of labor.</span></span></span></p>"
      },
      {
        "id": 16434,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Goserelin:&nbsp; Growth hormone deficiency</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following agents are correctly paired with an appropriate clinical use of the drug except.</span></span></span></p>",
    "unique_key": "Q9557041",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407296,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Goserelin: Growth hormone deficiency</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Goserelin </strong>is a<strong> gonadotropin-releasing hormone (GnRH) agonist,</strong> <strong>not </strong>used for the treatment of<strong> growth hormone deficiency</strong>. It is commonly used in the<strong> treatment of hormone-sensitive cancers </strong>such as <strong>prostate cancer in men and breast cancer in premenopausal women</strong>, as well as for<strong> endometriosis </strong>and in assisted reproduction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Desmopressin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Desmopressin is a <strong>synthetic analogue of vasopressin</strong> and is drug of choice for the treatment of <strong>central</strong> <strong>diabetes insipidus and nocturnal enuresis.</strong> It is also used for managing<strong> bleeding</strong> in patients<strong> with von Willebrand disease and mild hemophilia A </strong>due to its ability to<strong> increase the levels of von Willebrand factor and factor VIII</strong>.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Octreotide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Octreotide is a<strong> somatostatin analogue </strong>that can <strong>reduce portal blood flow </strong>and is <strong>used</strong> in the management of <strong>bleeding esophageal varices</strong> as an adjunct to specific treatments like <strong>endoscopic band ligation or sclerotherapy.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Oxytocin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Oxytocin is a <strong>peptide hormone </strong>and is<strong> drug of choice </strong>to<strong> induce labor in pregnant women</strong> who are <strong>at or near</strong> term when there is a medical reason for<strong> inducing labor, or to strengthen labor contractions during childbirth.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Goserelin </strong>is a <strong>GnRH agonist </strong>used primarily in the treatment of<strong> hormone-sensitive cancers </strong>and is<strong> not indicated for growth hormone</strong> <strong>deficiency,</strong> which would require<strong> growth hormone therapy </strong>or other <strong>specific treatments</strong> related to<strong> growth hormone biosynthesis or</strong> <strong>action.</strong></span></span></p>",
    "correct_choice_id": 16434,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 4245,
    "choices": [
      {
        "id": 16957,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cortisol</span></span></span></p>"
      },
      {
        "id": 16958,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prednisolone</span></span></span></p>"
      },
      {
        "id": 16959,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Betamethasone</span></span></span></p>"
      },
      {
        "id": 16960,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrocortisone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Long term steroid therapy can lead to suppression of hypothalamic pituitary-adrenal axis. It can be overcome by using alternate day therapy with corticosteroids. Which of the following steroids is unsuitable for alternate day therapy for such purpose? </span></span></span></p>",
    "unique_key": "Q8334869",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407297,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Betamethasone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Betamethasone</strong> is a <strong>long-acting corticosteroid</strong> with a <strong>duration of action</strong> that generally exceeds <strong>48 hours. </strong>Because of its <strong>long</strong> d<strong>uration of action, </strong>betamethasone is<strong> unsuitable </strong>for <strong>alternate day</strong> therapy intended to <strong>minimize the suppression of the</strong> <strong>hypothalamic-pituitary-adrenal (HPA) axis.</strong> Alternate day therapy is designed to allow the <strong>HPA axis </strong>to <strong>recover on the off days,</strong> which is <strong>more feasible with corticosteroids</strong> that have a <strong>shorter duration of action.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Cortisol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Cortisol,</strong> also known as <strong>hydrocortisone</strong> when used as a medication, has a<strong> short duration of action, </strong>making it suitable for <strong>alternate day therapy.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Prednisolone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Prednisolone is an <strong>intermediate-acting corticosteroid </strong>that is commonly used in <strong>alternate day therapy to</strong> <strong>reduce HPA axis suppression.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hydrocortisone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hydrocortisone is <strong>essentially synthetic cortisol</strong> with a <strong>short duration of action</strong>, suitable for <strong>alternate day</strong> therapy to <strong>minimize HPA axis suppression.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Betamethasone&#39;s long duration of action</strong> makes it inappropriate for<strong> alternate day therapy </strong>designed to <strong>mitigate HPA axis</strong> <strong>suppression, </strong>unlike <strong>shorter-acting steroids like hydrocortisone</strong>, which are <strong>better </strong>suited for such <strong>treatment schedules.</strong></span></span></span></p>",
    "correct_choice_id": 16959,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 3647,
    "choices": [
      {
        "id": 14567,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Terlipressin is preferred over desmopressin for treatment of bleeding esophageal varices.</span></span></span></p>"
      },
      {
        "id": 14568,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin is not useful for treatment of nephrogenic diabetes insipidus.</span></span></span></p>"
      },
      {
        "id": 14569,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiloride is used for treatment of lithium induced diabetes insipidus.</span></span></span></p>"
      },
      {
        "id": 14570,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin can be used for treatment of both pituitary and renal diabetes insipidus.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements are true except.</span></span></span></p>",
    "unique_key": "Q4647351",
    "question_audio": null,
    "question_video": null,
    "map_id": 15407298,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Desmopressin can be used for treatment of both pituitary and renal diabetes insipidus.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is <strong>selective agonist of V2 receptors </strong>of vasopressin.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Diabetes insipidus (DI) of pituitary origin (neurogenic) </strong>is the most important <strong>indication for desmopressin.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is <strong>ineffective in renal (nephrogenic) Dl </strong>since the<strong> kidney is unresponsive to ADH.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therefore, <strong>desmopressin is the drug of choice for central diabetes insipidus </strong>and <strong>not </strong>much effective <strong>against nephrogenic diabetes insipidus.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be used by<strong> intranasal route and oral routes</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clinical Indications: </span></span></span>\r\n\t<ul>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Central diabetes insipidus.</span></span></span></strong></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nocturnal enuresis in children.</span></span></span></strong></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemophilia.</span></span></span></strong></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">von Willebrand&rsquo;s Disease.</span></span></span></strong></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In case of esophageal variceal bleeding:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Terlipressin </strong>&iexcl;s a <strong>synthetic analogue of vasopressin </strong>with <strong>V1 agonistic action</strong>. It has <strong>longer activity and fewer side effects.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It <strong>reduces</strong> <strong>portal pressure </strong>and can be used in<strong> esophageal variceal bleeding.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Desmopressin </strong>has shown<strong> no clinical benefits </strong>&iexcl;n the setting of <strong>variceal bleeding.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In case of lithium induced diabetes insipidus</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiloride </strong>is the <strong>drug of choice</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It <strong>blocks </strong>entry of<strong> Li+ through Na+ channels in the CD cells </strong>and mitigates<strong> diabetes insipidus </strong>induced by<strong> lithium</strong>. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Terlipressin is preferred over desmopressin for treatment of bleeding esophageal varices:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>True.</strong> Terlipressin, a <strong>synthetic</strong> <strong>analogue of vasopressin </strong>with <strong>V1 agonistic</strong> action, <strong>reduces portal pressure</strong> and is preferred in the<strong> treatment of esophageal variceal bleeding </strong>due to its<strong> longer activity and fewer side effects.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Desmopressin is not useful for treatment of nephrogenic diabetes insipidus:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> True. </strong>Desmopressin is<strong> ineffective </strong>in <strong>nephrogenic DI</strong> because the <strong>kidney does not respond to ADH.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Amiloride is used for treatment of lithium induced diabetes insipidus:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>True</strong>. Amiloride <strong>blocks </strong>the <strong>entry of lithium ions</strong> through <strong>sodium channels in the collecting duct cells</strong>, effectively <strong>mitigating the diabetes insip</strong>idus induced by<strong> lithium.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Desmopressin </strong>is effective for treating<strong> central diabetes insipidus </strong>because it <strong>acts on V2 receptors </strong>to <strong>mitigate the symptoms</strong>, but it <strong>does not </strong>work for<strong> nephrogenic diabetes insipidus</strong>, where the <strong>kidney is unresponsive to ADH</strong>.</span></span></span></p>",
    "correct_choice_id": 14570,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  }
];
        let quizName = '00003 Mid Day Module (Pharma-3)';
        const quizFilename = '00003-mid-day-module-pharma-3-c9e061d7.html';
        let hierarchy = ["Cerebellum", "Mock Test", "Mid Day Module"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        // --- NEW: History Management ---
        function saveProgress() {
            if (isQuizCompleted) return; // Don't save after completion
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            userHistory[quizFilename] = {
                questionStates,
                stats,
                currentQuestionIndex,
                currentMode,
                status: 'incomplete',
                lastSeen: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }

        function loadProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const savedState = userHistory[quizFilename];
            if (savedState) {
                questionStates = savedState.questionStates;
                stats = savedState.stats;
                currentQuestionIndex = savedState.currentQuestionIndex;
                currentMode = savedState.currentMode;
                console.log('Progress loaded.');
                return true;
            }
            return false;
        }

        function clearProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            if(userHistory[quizFilename]) {
                delete userHistory[quizFilename];
                localStorage.setItem('userHistory', JSON.stringify(userHistory));
                console.log('Previous progress cleared.');
            }
        }

        function markQuizAsCompleted() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const totalQuestions = questionsData.length;
            const correct = stats.correctAnswers || 0;
            
            userHistory[quizFilename] = {
                score: correct,
                total: totalQuestions,
                status: 'completed',
                completedOn: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }
        // --- End of History Management ---

        const urlParams = new URLSearchParams(window.location.search);
        const startAt = parseInt(urlParams.get('startAt'));
        const resume = urlParams.get('resume') === 'true';

        function goBack() {
            if (!isQuizCompleted) saveProgress(); // Save progress before leaving
            window.location.href = document.referrer || 'index.html';
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            if (!isNaN(startAt) && startAt >= 0 && startAt < questionsData.length) {
                currentQuestionIndex = startAt;
            }

            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                processAnswer();
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
            saveProgress(); // NEW: Save on navigation
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            showSolution();
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            stats.correctAnswers = correct; // Update global stats
            stats.incorrectAnswers = incorrect;
            markQuizAsCompleted(); // NEW: Mark quiz as complete in history
            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                clearProgress(); // NEW: Clear history on retake
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                        saveProgress();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (resume) {
                if (loadProgress()) {
                    document.getElementById('modeModal').style.display = 'none';
                    initializeQuiz(); // Resume directly into the saved mode and state
                } else {
                    // If resume fails (e.g., cleared history), start fresh
                    clearProgress();
                    document.getElementById('modeModal').style.display = 'flex';
                }
             } else if (!window.location.pathname.endsWith('custom_quiz.html')) {
                clearProgress(); // Clear old progress if not resuming
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>